Raras
Buscar doenças, sintomas, genes...
Doença neurodegenerativa genética
ORPHA:183500DOENÇA RARA

Uma doença hereditária, caracterizada pela piora gradual e pelo enfraquecimento do sistema nervoso.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Uma doença hereditária, caracterizada pela piora gradual e pelo enfraquecimento do sistema nervoso.

Publicações científicas
71 artigos
Último publicado: 2026 Apr 9
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
308 sintomas
🦴
Ossos e articulações
184 sintomas
💪
Músculos
164 sintomas
👁️
Olhos
147 sintomas
😀
Face
94 sintomas
🫃
Digestivo
67 sintomas

+ 1124 sintomas em outras categorias

Características mais comuns

Pé cavo
Tecido adiposo intra-abdominal reduzido
Lipodistrofia generalizada
Deformidades congênitas de contratura do pé
Morfologia cerebral anormal
Demência semântica
2481sintomas
Sem dados (2481)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 2481 características clínicas mais associadas, ordenadas por frequência.

Pé cavoPes cavus
Tecido adiposo intra-abdominal reduzidoReduced intraabdominal adipose tissue
Lipodistrofia generalizadaGeneralized lipodystrophy
Deformidades congênitas de contratura do péCongenital foot contraction deformities
Morfologia cerebral anormalAbnormal cerebral morphology

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico71PubMed
Últimos 10 anos50publicações
Pico20229 papers
Linha do tempo
2026Hoje · 2026🧪 1981Primeiro ensaio clínico📈 2022Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

94 genes identificados com associação a esta condição.

DARS1Aspartate--tRNA ligase, cytoplasmicDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (3)
Selenoamino acid metabolismCytosolic tRNA aminoacylationTranscriptional and post-translational regulation of MITF-M expression and activity
MECANISMO DE DOENÇA

Hypomyelination with brainstem and spinal cord involvement and leg spasticity

An autosomal recessive leukoencephalopathy characterized by onset in the first year of life of severe spasticity, mainly affecting the lower limbs and resulting in an inability to achieve independent ambulation. Affected individuals show delayed motor development and nystagmus; some may have mild intellectual disability. Brain MRI shows hypomyelination and white matter lesions in the cerebrum, brainstem, cerebellum, and spinal cord.

OUTRAS DOENÇAS (1)
hypomyelination with brain stem and spinal cord involvement and leg spasticity
HGNC:2678UniProt:P14868
TMEM240Transmembrane protein 240Candidate gene tested inAltamente restrito
LOCALIZAÇÃO

SynapseCell membrane

MECANISMO DE DOENÇA

Spinocerebellar ataxia 21

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA21 is characterized by onset in the first decades of life of slowly progressive relatively mild cerebellar ataxia associated with slight extrapyramidal features predominant in older patients and cognitive impairment predominant in younger patients.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
59.7 TPM
Cerebelo
57.9 TPM
Brain Frontal Cortex BA9
28.4 TPM
Córtex cerebral
26.7 TPM
Brain Nucleus accumbens basal ganglia
22.9 TPM
OUTRAS DOENÇAS (1)
spinocerebellar ataxia type 21
HGNC:25186UniProt:Q5SV17
MECREnoyl-[acyl-carrier-protein] reductase, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the NADPH-dependent reduction of trans-2-enoyl thioesters in mitochondrial fatty acid synthesis (fatty acid synthesis type II). Fatty acid chain elongation in mitochondria uses acyl carrier protein (ACP) as an acyl group carrier, but the enzyme accepts both ACP and CoA thioesters as substrates in vitro. Displays a preference for medium-chain over short- and long-chain substrates (PubMed:12654921, PubMed:18479707, PubMed:27817865). May provide the octanoyl chain used for lipoic acid bio

LOCALIZAÇÃO

MitochondrionCytoplasmNucleus

VIAS BIOLÓGICAS (1)
Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA
MECANISMO DE DOENÇA

Dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities

An autosomal recessive neurologic disorder characterized by childhood-onset dystonia, basal ganglia degeneration and optic atrophy with decreased visual acuity. Dystonia is defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYTOABG severity is variable, and some patients lose independent ambulation.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
16.3 TPM
Nervo tibial
15.9 TPM
Útero
15.8 TPM
Cervix Endocervix
15.2 TPM
Cervix Ectocervix
14.8 TPM
OUTRAS DOENÇAS (3)
dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalitiesoptic atrophy 16obsolete autosomal recessive optic atrophy
HGNC:19691UniProt:Q9BV79
TMEM106BTransmembrane protein 106BCandidate gene tested inTolerante
FUNÇÃO

In neurons, involved in the transport of late endosomes/lysosomes (PubMed:25066864). May be involved in dendrite morphogenesis and maintenance by regulating lysosomal trafficking (PubMed:25066864). May act as a molecular brake for retrograde transport of late endosomes/lysosomes, possibly via its interaction with MAP6 (By similarity). In motoneurons, may mediate the axonal transport of lysosomes and axonal sorting at the initial segment (By similarity). It remains unclear whether TMEM106B affect

LOCALIZAÇÃO

Late endosome membraneLysosome membraneCell membrane

MECANISMO DE DOENÇA

Frontotemporal dementia 2

A form of dementia characterized by pathologic finding of frontotemporal lobar degeneration, presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. Gestural apraxia, parkinsonism, visual loss, and visual hallucinations are present in 25 to 40% of patients.

EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Endocervix
14.8 TPM
Útero
14.5 TPM
Cervix Ectocervix
14.3 TPM
Glândula adrenal
13.7 TPM
Fallopian Tube
12.2 TPM
OUTRAS DOENÇAS (4)
leukodystrophy, hypomyelinating, 16behavioral variant of frontotemporal dementiaprogressive non-fluent aphasiasemantic dementia
HGNC:22407UniProt:Q9NUM4
ATN1Atrophin-1Candidate gene tested inAltamente restrito
FUNÇÃO

Transcriptional corepressor. Recruits NR2E1 to repress transcription. Promotes vascular smooth cell (VSMC) migration and orientation (By similarity). Corepressor of MTG8 transcriptional repression. Has some intrinsic repression activity which is independent of the number of poly-Gln (polyQ) repeats

LOCALIZAÇÃO

NucleusCytoplasm, perinuclear regionCell junction

VIAS BIOLÓGICAS (1)
Regulation of PTEN gene transcription
MECANISMO DE DOENÇA

Dentatorubral-pallidoluysian atrophy

Autosomal dominant neurodegenerative disorder characterized by a loss of neurons in the dentate nucleus, rubrum, glogus pallidus and Luys'body. Clinical features are myoclonus epilepsy, dementia, and cerebellar ataxia. Onset of the disease occurs usually in the second decade of life and death in the fourth.

OUTRAS DOENÇAS (2)
dentatorubral-pallidoluysian atrophycongenital hypotonia, epilepsy, developmental delay, and digital anomalies
HGNC:3033UniProt:P54259
MT-ND2NADH-ubiquinone oxidoreductase chain 2Candidate gene tested inDesconhecido
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:16996290). Essential for the catalytic activity and assembly of complex I (PubMed:16996290)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Respiratory electron transportComplex I biogenesisMitochondrial translation terminationMitochondrial protein degradation
MECANISMO DE DOENÇA

Leber hereditary optic neuropathy

A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.

OUTRAS DOENÇAS (4)
mitochondrial diseaseLeber hereditary optic neuropathymaternally-inherited Leigh syndromemitochondrial complex I deficiency
HGNC:7456UniProt:P03891
ATXN3Ataxin-3Candidate gene tested inTolerante
FUNÇÃO

Deubiquitinating enzyme involved in protein homeostasis maintenance, transcription, cytoskeleton regulation, myogenesis and degradation of misfolded chaperone substrates (PubMed:12297501, PubMed:16118278, PubMed:17696782, PubMed:23625928, PubMed:28445460, PubMed:33157014). Binds long polyubiquitin chains and trims them, while it has weak or no activity against chains of 4 or less ubiquitins (PubMed:17696782). Involved in degradation of misfolded chaperone substrates via its interaction with STUB

LOCALIZAÇÃO

Nucleus matrixNucleusLysosome membrane

VIAS BIOLÓGICAS (2)
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genesJosephin domain DUBs
MECANISMO DE DOENÇA

Spinocerebellar ataxia 3

Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to cerebellum degeneration with variable involvement of the brainstem and spinal cord. SCA3 belongs to the autosomal dominant cerebellar ataxias type I (ADCA I) which are characterized by cerebellar ataxia in combination with additional clinical features like optic atrophy, ophthalmoplegia, bulbar and extrapyramidal signs, peripheral neuropathy and dementia. The molecular defect in SCA3 is the a CAG repeat expansion in ATX3 coding region. Longer expansions result in earlier onset and more severe clinical manifestations of the disease.

OUTRAS DOENÇAS (5)
Machado-Joseph diseaseMachado-Joseph disease type 3Machado-Joseph disease type 2Machado-Joseph disease type 1
HGNC:7106UniProt:P54252
SAMD9LSterile alpha motif domain-containing protein 9-likeCandidate gene tested inTolerante
FUNÇÃO

May be involved in endosome fusion. Mediates down-regulation of growth factor signaling via internalization of growth factor receptors

LOCALIZAÇÃO

Early endosomeMitochondrion

MECANISMO DE DOENÇA

Ataxia-pancytopenia syndrome

An autosomal dominant disorder characterized by cerebellar ataxia, variable hematologic cytopenias, and predisposition to bone marrow failure and myeloid leukemia.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
55.2 TPM
Baço
34.1 TPM
Pulmão
22.9 TPM
Nervo tibial
17.2 TPM
Cervix Endocervix
14.3 TPM
OUTRAS DOENÇAS (4)
monosomy 7 myelodysplasia and leukemia syndrome 1ataxia-pancytopenia syndromespinocerebellar ataxia 49SAMD9L-associated autoinflammatory syndrome
HGNC:1349UniProt:Q8IVG5
ASCC1Activating signal cointegrator 1 complex subunit 1Candidate gene tested inTolerante
FUNÇÃO

Plays a role in DNA damage repair as component of the ASCC complex (PubMed:29997253). Part of the ASC-1 complex that enhances NF-kappa-B, SRF and AP1 transactivation (PubMed:12077347). In cells responding to gastrin-activated paracrine signals, it is involved in the induction of SERPINB2 expression by gastrin. May also play a role in the development of neuromuscular junction

LOCALIZAÇÃO

NucleusNucleus speckle

VIAS BIOLÓGICAS (1)
ALKBH3 mediated reversal of alkylation damage
MECANISMO DE DOENÇA

Barrett esophagus

A condition characterized by a metaplastic change in which normal esophageal squamous epithelium is replaced by a columnar and intestinal-type epithelium. Patients with Barrett esophagus have an increased risk of esophageal adenocarcinoma. The main cause of Barrett esophagus is gastroesophageal reflux. The retrograde movement of acid and bile salts from the stomach into the esophagus causes prolonged injury to the esophageal epithelium and induces chronic esophagitis, which in turn is believed to trigger the pathologic changes.

OUTRAS DOENÇAS (3)
spinal muscular atrophy with congenital bone fractures 2Barrett esophagusprenatal-onset spinal muscular atrophy with congenital bone fractures
HGNC:24268UniProt:Q8N9N2
MT-ATP6ATP synthase F(0) complex subunit aCandidate gene tested inDesconhecido
FUNÇÃO

Subunit a, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain (Probable). ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). These two domains are linked by a central stalk rotating inside the F(1

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Mitochondrial translation terminationFormation of ATP by chemiosmotic couplingCristae formationMitochondrial protein degradation
MECANISMO DE DOENÇA

Neuropathy, ataxia, and retinitis pigmentosa

A syndrome characterized by variable combination of developmental delay, psychomotor retardation, hearing loss, optic atrophy and retinitis pigmentosa, dementia, seizures, ataxia, proximal neurogenic muscle weakness, and sensory neuropathy.

OUTRAS DOENÇAS (8)
mitochondrial diseasematernally-inherited Leigh syndromefamilial infantile bilateral striatal necrosismitochondrial proton-transporting ATP synthase complex deficiency
HGNC:7414UniProt:P00846
CCDC88CProtein DapleCandidate gene tested inTolerante
FUNÇÃO

Required for activation of guanine nucleotide-binding proteins (G-proteins) during non-canonical Wnt signaling (PubMed:26126266). Binds to ligand-activated Wnt receptor FZD7, displacing DVL1 from the FZD7 receptor and leading to inhibition of canonical Wnt signaling (PubMed:26126266). Acts as a non-receptor guanine nucleotide exchange factor by also binding to guanine nucleotide-binding protein G(i) alpha (Gi-alpha) subunits, leading to their activation (PubMed:26126266). Binding to Gi-alpha sub

LOCALIZAÇÃO

CytoplasmCell junction

VIAS BIOLÓGICAS (1)
Negative regulation of TCF-dependent signaling by DVL-interacting proteins
MECANISMO DE DOENÇA

Hydrocephalus, congenital, 1

A form of congenital hydrocephalus, a disease characterized by onset in utero of enlarged ventricles due to accumulation of ventricular cerebrospinal fluid. Affected individuals may have neurologic impairment. HYC1 inheritance is autosomal recessive.

INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (3)
hydrocephalus, nonsyndromic, autosomal recessive 1spinocerebellar ataxia type 40congenital non-communicating hydrocephalus
HGNC:19967UniProt:Q9P219
ASPAAspartoacylaseCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the deacetylation of N-acetylaspartic acid (NAA) to produce acetate and L-aspartate. NAA occurs in high concentration in brain and its hydrolysis NAA plays a significant part in the maintenance of intact white matter. In other tissues it acts as a scavenger of NAA from body fluids

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Aspartate and asparagine metabolism
MECANISMO DE DOENÇA

Canavan disease

A rare neurodegenerative condition of infancy or childhood characterized by white matter vacuolization and demyelination that gives rise to a spongy appearance. The clinical features are onset in early infancy, atonia of neck muscles, hypotonia, hyperextension of legs and flexion of arms, blindness, severe mental defect, megalocephaly, and death by 18 months on the average.

OUTRAS DOENÇAS (3)
Canavan diseasesevere Canavan diseasemild Canavan disease
HGNC:756UniProt:P45381
ITM2BIntegral membrane protein 2BCandidate gene tested inModerado
FUNÇÃO

Plays a regulatory role in the processing of the amyloid-beta A4 precursor protein (APP) and acts as an inhibitor of the amyloid-beta peptide aggregation and fibrils deposition. Plays a role in the induction of neurite outgrowth. Functions as a protease inhibitor by blocking access of secretases to APP cleavage sites Mature BRI2 (mBRI2) functions as a modulator of the amyloid-beta A4 precursor protein (APP) processing leading to a strong reduction in the secretion of secretase-processed amyloid-

LOCALIZAÇÃO

Golgi apparatus membraneCell membraneEndosome membraneSecreted

VIAS BIOLÓGICAS (1)
Amyloid fiber formation
MECANISMO DE DOENÇA

Cerebral amyloid angiopathy, ITM2B-related 1

A disorder characterized by amyloid deposition in the walls of cerebral blood vessels and neurodegeneration in the central nervous system. Cerebral amyloid angiopathy, non-neuritic and perivascular plaques and neurofibrillary tangles are the predominant pathological lesions. Clinical features include progressive mental deterioration, spasticity and muscular rigidity.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
241.1 TPM
Sangue
208.7 TPM
Cérebro - Hemisfério cerebelar
204.2 TPM
Cervix Ectocervix
200.0 TPM
Cervix Endocervix
193.0 TPM
INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (3)
ABri amyloidosisADan amyloidosisretinal dystrophy with inner retinal dysfunction and ganglion cell anomalies
HGNC:6174UniProt:Q9Y287
MALMyelin and lymphocyte proteinCandidate gene tested inRestrito
FUNÇÃO

May be involved in vesicular trafficking from the Golgi apparatus to the cell membrane. Plays a role in the maintenance of the myelin sheath, and in axon-glia and glia-glia interactions

LOCALIZAÇÃO

MembraneCell membrane

VIAS BIOLÓGICAS (1)
MyD88:MAL(TIRAP) cascade initiated on plasma membrane
MECANISMO DE DOENÇA

Leukodystrophy, hypomyelinating, 28

A form of hypomyelinating leukodystrophy, a group of heterogeneous disorders characterized by persistent deficit of myelin observed on brain imaging. HLD28 is an autosomal recessive form characterized by developmental delay and nystagmus in infancy, followed by significant learning disabilities and progressive motor deterioration within the first decade.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
2397.9 TPM
Vagina
634.4 TPM
Nervo tibial
516.1 TPM
Rim - Medula
404.5 TPM
Brain Spinal cord cervical c-1
310.4 TPM
INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (2)
leukodystrophy, hypomyelinating, 28Pelizaeus-Merzbacher-like disease
HGNC:6817UniProt:P21145
PLP1Myelin proteolipid proteinCandidate gene tested inAltamente restrito
FUNÇÃO

This is the major myelin protein from the central nervous system. It plays an important role in the formation or maintenance of the multilamellar structure of myelin

LOCALIZAÇÃO

Cell membraneMyelin membrane

MECANISMO DE DOENÇA

Leukodystrophy, hypomyelinating, 1

An X-linked recessive disorder of the central nervous system in which myelin is not formed properly. Clinically characterized by nystagmus, spastic quadriplegia, ataxia, and developmental delay.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
7479.9 TPM
Substância negra
1825.4 TPM
Hipocampo
1337.1 TPM
Brain Putamen basal ganglia
995.4 TPM
Cérebro - Amígdala
861.3 TPM
OUTRAS DOENÇAS (8)
Pelizeaus-Merzbacher spectrum disorderhereditary spastic paraplegia 2Pelizaeus-Merzbacher disease in female carriersnull syndrome
HGNC:9086UniProt:P60201
SMN2Survival motor neuron proteinCandidate gene tested inModerado
FUNÇÃO

The SMN complex catalyzes the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome, and thereby plays an important role in the splicing of cellular pre-mRNAs (PubMed:18984161, PubMed:9845364). Most spliceosomal snRNPs contain a common set of Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP (Sm core) (PubMed:18984161). In the cytosol,

LOCALIZAÇÃO

Nucleus, gemNucleus, Cajal bodyCytoplasmCytoplasmic granulePerikaryonCell projection, neuron projectionCell projection, axonCytoplasm, myofibril, sarcomere, Z line

VIAS BIOLÓGICAS (2)
snRNP AssemblySARS-CoV-2 modulates host translation machinery
MECANISMO DE DOENÇA

Spinal muscular atrophy 1

A form of spinal muscular atrophy, a group of neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. Autosomal recessive forms are classified according to the age of onset, the maximum muscular activity achieved, and survivorship. The severity of the disease is mainly determined by the copy number of SMN2, a copy gene which predominantly produces exon 7-skipped transcripts and only low amount of full-length transcripts that encode for a protein identical to SMN1. Only about 4% of SMA patients bear one SMN1 copy with an intragenic mutation. SMA1 is a severe form, with onset before 6 months of age. SMA1 patients never achieve the ability to sit.

EXPRESSÃO TECIDUAL(Baixa expressão)
Cervix Ectocervix
4.9 TPM
Ovário
4.9 TPM
Testículo
4.5 TPM
Útero
4.4 TPM
Linfócitos
4.2 TPM
OUTRAS DOENÇAS (4)
spinal muscular atrophy, type IVspinal muscular atrophy, type 1spinal muscular atrophy, type IIspinal muscular atrophy, type III
HGNC:11118UniProt:Q16637
RPGRIP1LProtein fantomCandidate gene tested inTolerante
FUNÇÃO

Negatively regulates signaling through the G-protein coupled thromboxane A2 receptor (TBXA2R) (PubMed:19464661). May be involved in mechanisms like programmed cell death, craniofacial development, patterning of the limbs, and formation of the left-right axis (By similarity). Involved in the organization of apical junctions; the function is proposed to implicate a NPHP1-4-8 module. Does not seem to be strictly required for ciliogenesis (PubMed:19464661). Involved in establishment of planar cell p

LOCALIZAÇÃO

CytoplasmCytoplasm, cytoskeleton, cilium basal bodyCytoplasm, cytoskeleton, cilium axonemeCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCell junction, tight junction

VIAS BIOLÓGICAS (2)
Hedgehog 'off' stateAnchoring of the basal body to the plasma membrane
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
9.1 TPM
Fibroblastos
7.3 TPM
Pituitária
5.6 TPM
Ovário
3.0 TPM
Cervix Endocervix
3.0 TPM
OUTRAS DOENÇAS (6)
Meckel syndrome, type 5Joubert syndrome 7COACH syndrome 3COACH syndrome
HGNC:29168UniProt:Q68CZ1
GRM1Metabotropic glutamate receptor 1Candidate gene tested inAltamente restrito
FUNÇÃO

G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol-calcium second messenger system. May participate in the central action of glutamate in the CNS, such as long-term potentiation in the hippocampus and long-term depression in the cerebellum (PubMed:24603153, PubMed:28886343, PubMed:7476890).

LOCALIZAÇÃO

Cell membranePostsynaptic cell membraneCell projection, dendrite

VIAS BIOLÓGICAS (3)
G alpha (q) signalling eventsClass C/3 (Metabotropic glutamate/pheromone receptors)Neurexins and neuroligins
MECANISMO DE DOENÇA

Spinocerebellar ataxia, autosomal recessive, 13

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR13 is characterized by delayed psychomotor development beginning in infancy. Affected individuals show mild to profound intellectual disability with poor or absent speech as well as gait and stance ataxia and hyperreflexia.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
38.4 TPM
Cerebelo
30.6 TPM
Brain Frontal Cortex BA9
5.7 TPM
Córtex cerebral
3.6 TPM
Brain Anterior cingulate cortex BA24
3.6 TPM
OUTRAS DOENÇAS (3)
spinocerebellar ataxia 44autosomal recessive spinocerebellar ataxia 13chondromyxoid fibroma
HGNC:4593UniProt:Q13255
LSM11U7 snRNA-associated Sm-like protein LSm11Candidate gene tested inTolerante
FUNÇÃO

Component of the U7 snRNP complex that is involved in the histone 3'-end pre-mRNA processing (PubMed:11574479, PubMed:16914750, PubMed:33230297). Increases U7 snRNA levels but not histone 3'-end pre-mRNA processing activity, when overexpressed (PubMed:11574479, PubMed:16914750). Required for cell cycle progression from G1 to S phases (By similarity). Binds specifically to the Sm-binding site of U7 snRNA (PubMed:11574479, PubMed:16914750)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (3)
SLBP independent Processing of Histone Pre-mRNAsRNA Polymerase II Transcription TerminationSLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs
MECANISMO DE DOENÇA

Aicardi-Goutieres syndrome 8

A form of Aicardi-Goutieres syndrome, a genetically heterogeneous disease characterized by cerebral atrophy, leukoencephalopathy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infection. Clinical features as thrombocytopenia, hepatosplenomegaly and elevated hepatic transaminases along with intermittent fever may erroneously suggest an infective process. Severe neurological dysfunctions manifest in infancy as progressive microcephaly, spasticity, dystonic posturing and profound psychomotor retardation. Death often occurs in early childhood. AGS8 inheritance is autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Muscular
19.5 TPM
Bladder
17.4 TPM
Cérebro - Hemisfério cerebelar
16.2 TPM
Cerebelo
12.9 TPM
Útero
12.7 TPM
OUTRAS DOENÇAS (2)
Aicardi-Goutieres syndrome 8Aicardi-Goutieres syndrome
HGNC:30860UniProt:P83369
TREX1Three-prime repair exonuclease 1Candidate gene tested inTolerante
FUNÇÃO

Major cellular 3'-to-5' DNA exonuclease which digests single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) with mismatched 3' termini (PubMed:10391904, PubMed:10393201, PubMed:17293595). Prevents cell-intrinsic initiation of autoimmunity (PubMed:10391904, PubMed:10393201, PubMed:17293595). Acts by metabolizing DNA fragments from endogenous retroelements, including L1, LTR and SINE elements (PubMed:10391904, PubMed:10393201, PubMed:17293595). Plays a key role in degradation of DNA fragment

LOCALIZAÇÃO

NucleusCytoplasm, cytosolEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (2)
IRF3-mediated induction of type I IFNRegulation by TREX1
MECANISMO DE DOENÇA

Aicardi-Goutieres syndrome 1

A form of Aicardi-Goutieres syndrome, a genetically heterogeneous disease characterized by cerebral atrophy, leukoencephalopathy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infection. Clinical features as thrombocytopenia, hepatosplenomegaly and elevated hepatic transaminases along with intermittent fever may erroneously suggest an infective process. Severe neurological dysfunctions manifest in infancy as progressive microcephaly, spasticity, dystonic posturing and profound psychomotor retardation. Death often occurs in early childhood.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
80.6 TPM
Baço
45.2 TPM
Skin Sun Exposed Lower leg
42.6 TPM
Skin Not Sun Exposed Suprapubic
42.3 TPM
Pituitária
42.0 TPM
OUTRAS DOENÇAS (6)
retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestationschilblain lupus 1Aicardi-Goutieres syndrome 1Aicardi-Goutieres syndrome
HGNC:12269UniProt:Q9NSU2
RNASEH2CRibonuclease H2 subunit CCandidate gene tested inTolerante
FUNÇÃO

Non catalytic subunit of RNase H2, an endonuclease that specifically degrades the RNA of RNA:DNA hybrids. Participates in DNA replication, possibly by mediating the removal of lagging-strand Okazaki fragment RNA primers during DNA replication. Mediates the excision of single ribonucleotides from DNA:RNA duplexes

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Aicardi-Goutieres syndrome 3

A form of Aicardi-Goutieres syndrome, a genetically heterogeneous disease characterized by cerebral atrophy, leukoencephalopathy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infection. Clinical features as thrombocytopenia, hepatosplenomegaly and elevated hepatic transaminases along with intermittent fever may erroneously suggest an infective process. Severe neurological dysfunctions manifest in infancy as progressive microcephaly, spasticity, dystonic posturing and profound psychomotor retardation. Death often occurs in early childhood.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
70.5 TPM
Cérebro - Hemisfério cerebelar
68.3 TPM
Útero
67.2 TPM
Ovário
60.3 TPM
Cervix Endocervix
59.7 TPM
OUTRAS DOENÇAS (2)
Aicardi-Goutieres syndrome 3Aicardi-Goutieres syndrome
HGNC:24116UniProt:Q8TDP1
ARL6IP1ADP-ribosylation factor-like protein 6-interacting protein 1Candidate gene tested inTolerante
FUNÇÃO

Positively regulates SLC1A1/EAAC1-mediated glutamate transport by increasing its affinity for glutamate in a PKC activity-dependent manner. Promotes the catalytic efficiency of SLC1A1/EAAC1 probably by reducing its interaction with ARL6IP5, a negative regulator of SLC1A1/EAAC1-mediated glutamate transport (By similarity). Plays a role in the formation and stabilization of endoplasmic reticulum tubules (PubMed:24262037). Negatively regulates apoptosis, possibly by modulating the activity of caspa

LOCALIZAÇÃO

Endomembrane systemEndoplasmic reticulum membraneEndoplasmic reticulum

MECANISMO DE DOENÇA

Spastic paraplegia 61, autosomal recessive

A complicated form of spastic paraplegia with polysensory and motor neuropathy. Spastic paraplegia is a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.

OUTRAS DOENÇAS (1)
hereditary spastic paraplegia 61
HGNC:697UniProt:Q15041
ERLIN1Erlin-1Candidate gene tested inTolerante
FUNÇÃO

Component of the ERLIN1/ERLIN2 complex which mediates the endoplasmic reticulum-associated degradation (ERAD) of inositol 1,4,5-trisphosphate receptors (IP3Rs). Involved in regulation of cellular cholesterol homeostasis by regulation the SREBP signaling pathway (PubMed:37683630). Binds cholesterol and may promote ER retention of the SCAP-SREBF complex (PubMed:24217618) (Microbial infection) Required early in hepatitis C virus (HCV) infection to initiate RNA replication, and later in the infectio

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (3)
AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274)ABC-family proteins mediated transportDefective CFTR causes cystic fibrosis
MECANISMO DE DOENÇA

Spastic paraplegia 62, autosomal recessive

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
58.3 TPM
Vagina
30.3 TPM
Fígado
28.9 TPM
Esôfago - Mucosa
25.4 TPM
Cervix Endocervix
24.5 TPM
OUTRAS DOENÇAS (1)
hereditary spastic paraplegia 62
HGNC:16947UniProt:O75477
FXNFrataxin, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Functions as an activator of persulfide transfer to the scaffoding protein ISCU as component of the core iron-sulfur cluster (ISC) assembly complex and participates to the [2Fe-2S] cluster assembly (PubMed:12785837, PubMed:24971490). Accelerates sulfur transfer from NFS1 persulfide intermediate to ISCU and to small thiols such as L-cysteine and glutathione leading to persulfuration of these thiols and ultimately sulfide release (PubMed:24971490). Binds ferrous ion and is released from FXN upon t

LOCALIZAÇÃO

MitochondrionCytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Mitochondrial protein import
MECANISMO DE DOENÇA

Friedreich ataxia

Autosomal recessive, progressive degenerative disease characterized by neurodegeneration and cardiomyopathy it is the most common inherited ataxia. The disorder is usually manifest before adolescence and is generally characterized by incoordination of limb movements, dysarthria, nystagmus, diminished or absent tendon reflexes, Babinski sign, impairment of position and vibratory senses, scoliosis, pes cavus, and hammer toe. In most patients, FRDA is due to GAA triplet repeat expansions in the first intron of the frataxin gene. But in some cases the disease is due to mutations in the coding region.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
12.5 TPM
Linfócitos
11.2 TPM
Glândula adrenal
10.8 TPM
Fibroblastos
10.6 TPM
Útero
9.3 TPM
OUTRAS DOENÇAS (2)
Friedreich ataxia 1Friedreich ataxia
HGNC:3951UniProt:Q16595
CPT1CPalmitoyl thioesterase CPT1CCandidate gene tested inTolerante
FUNÇÃO

Palmitoyl thioesterase specifically expressed in the endoplasmic reticulum of neurons. Modulates the trafficking of the glutamate receptor, AMPAR, to plasma membrane through depalmitoylation of GRIA1 (PubMed:30135643). Also regulates AMPR trafficking through the regulation of SACM1L phosphatidylinositol-3-phosphatase activity by interaction in a malonyl-CoA dependent manner (By similarity). Binds malonyl-CoA and couples malonyl-CoA to ceramide levels, necessary for proper spine maturation and co

LOCALIZAÇÃO

Cell projection, dendriteCell projection, axonEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Carnitine shuttle
MECANISMO DE DOENÇA

Spastic paraplegia 73, autosomal dominant

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.

OUTRAS DOENÇAS (1)
hereditary spastic paraplegia 73
HGNC:18540UniProt:Q8TCG5
SPARTSpartinCandidate gene tested inTolerante
FUNÇÃO

Lipophagy receptor that plays an important role in lipid droplet (LD) turnover in motor neurons (PubMed:37443287). Localizes to LDs and interacts with components of the autophagy machinery, such as MAP1LC3A/C proteins to deliver LDs to autophagosomes for degradation via lipophagy (PubMed:37443287). Lipid transfer protein required for lipid droplet degradation, including by lipophagy (PubMed:38190532). Can bind and transfer all lipid species found in lipid droplets, from phospholipids to triglyce

LOCALIZAÇÃO

CytoplasmMidbodyLipid droplet

MECANISMO DE DOENÇA

Spastic paraplegia 20, autosomal recessive

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG20 is characterized by dysarthria, distal amyotrophy, mild developmental delay and short stature.

OUTRAS DOENÇAS (1)
Troyer syndrome
HGNC:18514UniProt:Q8N0X7
MTTPMicrosomal triglyceride transfer protein large subunitCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the transport of triglyceride, cholesteryl ester, and phospholipid between phospholipid surfaces (PubMed:15897609, PubMed:16478722, PubMed:22236406, PubMed:23475612, PubMed:25108285, PubMed:26224785, PubMed:8876250, PubMed:8939939). Required for the assembly and secretion of plasma lipoproteins that contain apolipoprotein B (PubMed:16478722, PubMed:23475612, PubMed:26224785, PubMed:8876250, PubMed:8939939). May be involved in regulating cholesteryl ester biosynthesis in cells that prod

LOCALIZAÇÃO

Endoplasmic reticulumGolgi apparatus

VIAS BIOLÓGICAS (3)
VLDL assemblyChylomicron assemblyLDL remodeling
MECANISMO DE DOENÇA

Abetalipoproteinemia

An autosomal recessive disorder of lipoprotein metabolism. Affected individuals produce virtually no circulating apolipoprotein B-containing lipoproteins (chylomicrons, VLDL, LDL, lipoprotein(A)). Malabsorption of the antioxidant vitamin E occurs, leading to spinocerebellar and retinal degeneration.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
31.1 TPM
Intestino delgado
24.7 TPM
Testículo
7.1 TPM
Ovário
1.8 TPM
Linfócitos
1.2 TPM
OUTRAS DOENÇAS (1)
abetalipoproteinemia
HGNC:7467UniProt:P55157
DSTYKDual serine/threonine and tyrosine protein kinaseCandidate gene tested inAltamente restrito
FUNÇÃO

Acts as a positive regulator of ERK phosphorylation downstream of fibroblast growth factor-receptor activation (PubMed:23862974, PubMed:28157540). Involved in the regulation of both caspase-dependent apoptosis and caspase-independent cell death (PubMed:15178406). In the skin, it plays a predominant role in suppressing caspase-dependent apoptosis in response to UV stress in a range of dermal cell types (PubMed:28157540)

LOCALIZAÇÃO

CytoplasmCell membraneApical cell membraneBasolateral cell membraneCell junction

MECANISMO DE DOENÇA

Congenital anomalies of the kidney and urinary tract 1

A disorder encompassing a broad spectrum of renal and urinary tract malformations that include renal agenesis, kidney hypodysplasia, multicystic kidney dysplasia, duplex collecting system, posterior urethral valves and ureter abnormalities. Congenital anomalies of kidney and urinary tract are the commonest cause of chronic kidney disease in children.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
33.1 TPM
Cerebelo
25.4 TPM
Útero
16.7 TPM
Brain Frontal Cortex BA9
15.5 TPM
Ovário
14.8 TPM
OUTRAS DOENÇAS (3)
congenital anomalies of kidney and urinary tract 1hereditary spastic paraplegia 23renal agenesis, unilateral
HGNC:29043UniProt:Q6XUX3
POLR3ADNA-directed RNA polymerase III subunit RPC1Candidate gene tested inTolerante
FUNÇÃO

Catalytic core component of RNA polymerase III (Pol III), a DNA-dependent RNA polymerase which synthesizes small non-coding RNAs using the four ribonucleoside triphosphates as substrates. Synthesizes 5S rRNA, snRNAs, tRNAs and miRNAs from at least 500 distinct genomic loci (PubMed:19609254, PubMed:19631370, PubMed:20413673, PubMed:33335104, PubMed:33558764, PubMed:33558766, PubMed:34675218, PubMed:35637192, PubMed:9331371). Pol III-mediated transcription cycle proceeds through transcription init

LOCALIZAÇÃO

NucleusCytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Cytosolic sensors of pathogen-associated DNA
MECANISMO DE DOENÇA

Leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism

An autosomal recessive neurodegenerative disorder characterized by childhood onset of progressive motor decline manifest as spasticity, ataxia, tremor, and cerebellar signs, as well as mild cognitive regression. Other features may include hypodontia or oligodontia and hypogonadotropic hypogonadism. There is considerable inter- and intrafamilial variability.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
19.6 TPM
Cerebelo
18.6 TPM
Pituitária
15.8 TPM
Fibroblastos
14.5 TPM
Linfócitos
12.7 TPM
OUTRAS DOENÇAS (7)
leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadismWiedemann-Rautenstrauch syndrometremor-ataxia-central hypomyelination syndromeodontoleukodystrophy
HGNC:30074UniProt:O14802
EXOSC9Exosome complex component RRP45Candidate gene tested inTolerante
FUNÇÃO

Non-catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-products and non-coding 'pervasive' transcripts, such as antisense RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs with processing defe

LOCALIZAÇÃO

CytoplasmNucleusNucleus, nucleolusNucleus, nucleoplasm

VIAS BIOLÓGICAS (5)
mRNA decay by 3' to 5' exoribonucleaseATF4 activates genes in response to endoplasmic reticulum stressKSRP (KHSRP) binds and destabilizes mRNAButyrate Response Factor 1 (BRF1) binds and destabilizes mRNATristetraprolin (TTP, ZFP36) binds and destabilizes mRNA
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 1D

An autosomal recessive neurologic disorder with onset at birth or in infancy, and characterized by progressive axonal motor neuronopathy, severe generalized hypotonia, respiratory insufficiency, and cerebellar atrophy. Death in childhood may occur.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
43.9 TPM
Testículo
34.6 TPM
Fibroblastos
34.4 TPM
Nervo tibial
24.9 TPM
Cérebro - Hemisfério cerebelar
23.4 TPM
OUTRAS DOENÇAS (2)
pontocerebellar hypoplasia, type 1Dpontocerebellar hypoplasia type 1
HGNC:9137UniProt:Q06265
NAIPBaculoviral IAP repeat-containing protein 1Candidate gene tested inTolerante
FUNÇÃO

Anti-apoptotic protein which acts by inhibiting the activities of CASP3, CASP7 and CASP9. Can inhibit the autocleavage of pro-CASP9 and cleavage of pro-CASP3 by CASP9. Capable of inhibiting CASP9 autoproteolysis at 'Asp-315' and decreasing the rate of auto proteolysis at 'Asp-330'. Acts as a mediator of neuronal survival in pathological conditions. Prevents motor-neuron apoptosis induced by a variety of signals. Possible role in the prevention of spinal muscular atrophy that seems to be caused b

LOCALIZAÇÃO

EXPRESSÃO TECIDUAL(Tecido-específico)
Sangue
5.8 TPM
Baço
3.8 TPM
Pulmão
1.3 TPM
Testículo
1.0 TPM
Fallopian Tube
0.9 TPM
OUTRAS DOENÇAS (3)
spinal muscular atrophy, type 1spinal muscular atrophy, type IIspinal muscular atrophy, type III
HGNC:7634UniProt:Q13075
EEF2Elongation factor 2Candidate gene tested inAltamente restrito
FUNÇÃO

Catalyzes the GTP-dependent ribosomal translocation step during translation elongation (PubMed:26593721). During this step, the ribosome changes from the pre-translocational (PRE) to the post-translocational (POST) state as the newly formed A-site-bound peptidyl-tRNA and P-site-bound deacylated tRNA move to the P and E sites, respectively (PubMed:26593721). Catalyzes the coordinated movement of the two tRNA molecules, the mRNA and conformational changes in the ribosome (PubMed:26593721)

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Neutrophil degranulation
MECANISMO DE DOENÇA

Spinocerebellar ataxia 26

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
2998.1 TPM
Fibroblastos
2856.0 TPM
Linfócitos
2101.6 TPM
Cervix Endocervix
1850.1 TPM
Útero
1835.9 TPM
OUTRAS DOENÇAS (1)
spinocerebellar ataxia type 26
HGNC:3214UniProt:P13639
RNASET2Ribonuclease T2Candidate gene tested inTolerante
FUNÇÃO

Ribonuclease that plays an essential role in innate immune response by recognizing and degrading RNAs from microbial pathogens that are subsequently sensed by TLR8 (PubMed:31778653). Cleaves preferentially single-stranded RNA molecules between purine and uridine residues, which critically contributes to the supply of catabolic uridine and the generation of purine-2',3'-cyclophosphate-terminated oligoribonucleotides (PubMed:31778653, PubMed:38697119). In turn, RNase T2 degradation products promot

LOCALIZAÇÃO

SecretedLysosome lumenEndoplasmic reticulum lumenMitochondrion intermembrane space

VIAS BIOLÓGICAS (1)
Neutrophil degranulation
MECANISMO DE DOENÇA

Leukoencephalopathy, cystic, without megalencephaly

An infantile-onset syndrome of cerebral leukoencephalopathy. Affected newborns develop microcephaly and neurologic abnormalities including psychomotor impairment, seizures and sensorineural hearing impairment. The brain shows multifocal white matter lesions, anterior temporal lobe subcortical cysts, pericystic abnormal myelination, ventriculomegaly and intracranial calcifications.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
167.7 TPM
Baço
157.8 TPM
Sangue
156.0 TPM
Tireoide
45.5 TPM
Intestino delgado
41.5 TPM
OUTRAS DOENÇAS (1)
cystic leukoencephalopathy without megalencephaly
HGNC:21686UniProt:O00584
GPT2Alanine aminotransferase 2Candidate gene tested inTolerante
FUNÇÃO

Catalyzes the reversible transamination between alanine and 2-oxoglutarate to form pyruvate and glutamate

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Alanine metabolism
MECANISMO DE DOENÇA

Neurodevelopmental disorder with spastic paraplegia and microcephaly

An autosomal recessive syndrome characterized by severe psychomotor developmental delay, dysarthria, walking difficulties, moderately to severely impaired intellectual development, poor or absent speech, and progressive microcephaly.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
93.0 TPM
Estômago
87.0 TPM
Fígado
65.7 TPM
Glândula salivar
61.2 TPM
Skin Not Sun Exposed Suprapubic
59.9 TPM
OUTRAS DOENÇAS (1)
glutamate pyruvate transaminase 2 deficiency
HGNC:18062UniProt:Q8TD30
GFAPGlial fibrillary acidic proteinCandidate gene tested inTolerante
FUNÇÃO

GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Chaperone Mediated Autophagy
MECANISMO DE DOENÇA

Alexander disease

A rare disorder of the central nervous system. The most common form affects infants and young children, and is characterized by progressive failure of central myelination, usually leading to death within the first decade. Infants with Alexander disease develop a leukodystrophy with macrocephaly, seizures, and psychomotor retardation. Patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course. Histologically, Alexander disease is characterized by Rosenthal fibers, homogeneous eosinophilic inclusions in astrocytes.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Spinal cord cervical c-1
9333.8 TPM
Substância negra
3372.0 TPM
Hipotálamo
2922.2 TPM
Hipocampo
1638.7 TPM
Cérebro - Amígdala
1354.5 TPM
OUTRAS DOENÇAS (3)
Alexander diseaseAlexander disease type IAlexander disease type II
HGNC:4235UniProt:P14136
SETXHelicase senataxinCandidate gene tested inAltamente restrito
FUNÇÃO

ATP-dependent 5'->3' DNA/RNA helicase that preferentially unwinds RNA substrates over DNA, playing a crucial role in resolving R-loops and promoting transcription termination (PubMed:36864660). Plays a role in transcription regulation by its ability to modulate RNA Polymerase II (Pol II) binding to chromatin and through its interaction with proteins involved in transcription (PubMed:19515850, PubMed:21700224). Contributes to the mRNA splicing efficiency and splice site selection (PubMed:19515850

LOCALIZAÇÃO

NucleusNucleus, nucleoplasmNucleus, nucleolusCytoplasmChromosomeChromosome, telomereCell projection, axonCell projection, growth cone

MECANISMO DE DOENÇA

Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAN2 is an autosomal recessive form associated with peripheral neuropathy and elevated serum alpha-fetoprotein, immunoglobulins and, less commonly, creatine kinase levels. Some SCAN2 patients manifest oculomotor apraxia.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
50.4 TPM
Linfócitos
39.4 TPM
Tireoide
36.1 TPM
Baço
32.8 TPM
Pulmão
25.9 TPM
OUTRAS DOENÇAS (2)
spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2amyotrophic lateral sclerosis type 4
HGNC:445UniProt:Q7Z333
VRK1Serine/threonine-protein kinase VRK1Candidate gene tested inTolerante
FUNÇÃO

Serine/threonine kinase involved in the regulation of key cellular processes including the cell cycle, nuclear condensation, transcription regulation, and DNA damage response (PubMed:14645249, PubMed:18617507, PubMed:19103756, PubMed:33076429). Controls chromatin organization and remodeling by mediating phosphorylation of histone H3 on 'Thr-4' and histone H2AX (H2aXT4ph) (PubMed:31527692, PubMed:37179361). It also phosphorylates KAT5 in response to DNA damage, promoting KAT5 association with chr

LOCALIZAÇÃO

NucleusCytoplasmNucleus, Cajal body

VIAS BIOLÓGICAS (1)
Initiation of Nuclear Envelope (NE) Reformation
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 1A

A form of pontocerebellar hypoplasia, a disorder characterized by structural defects of the pons and cerebellum, evident upon brain imaging. PCH1A is an autosomal recessive form characterized by an abnormally small cerebellum and brainstem, central and peripheral motor dysfunction from birth, gliosis and spinal cord anterior horn cells degeneration resembling infantile spinal muscular atrophy. Additional features include muscle hypotonia, congenital contractures and respiratory insufficiency that is evident at birth.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
60.6 TPM
Testículo
41.3 TPM
Baço
13.9 TPM
Fibroblastos
12.9 TPM
Fallopian Tube
9.9 TPM
OUTRAS DOENÇAS (4)
neuronopathy, distal hereditary motor, autosomal recessive 10pontocerebellar hypoplasia type 1Apontocerebellar hypoplasia type 1microcephaly-complex motor and sensory axonal neuropathy syndrome
HGNC:12718UniProt:Q99986
EXOSC3Exosome complex component RRP40Candidate gene tested inTolerante
FUNÇÃO

Non-catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-products and non-coding 'pervasive' transcripts, such as antisense RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs with processing defe

LOCALIZAÇÃO

CytoplasmNucleus, nucleolusNucleus

VIAS BIOLÓGICAS (5)
mRNA decay by 3' to 5' exoribonucleaseATF4 activates genes in response to endoplasmic reticulum stressKSRP (KHSRP) binds and destabilizes mRNAButyrate Response Factor 1 (BRF1) binds and destabilizes mRNATristetraprolin (TTP, ZFP36) binds and destabilizes mRNA
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 1B

A severe autosomal recessive neurologic disorder characterized by a combination of cerebellar and spinal motor neuron degeneration beginning at birth. There is diffuse muscle weakness, progressive microcephaly, global developmental delay, and brainstem involvement.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
30.1 TPM
Testículo
28.1 TPM
Fibroblastos
21.2 TPM
Cervix Endocervix
16.4 TPM
Ovário
15.4 TPM
OUTRAS DOENÇAS (2)
pontocerebellar hypoplasia type 1Bpontocerebellar hypoplasia type 1
HGNC:17944UniProt:Q9NQT5
EXOSC8Exosome complex component RRP43Candidate gene tested inTolerante
FUNÇÃO

Non-catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-products and non-coding 'pervasive' transcripts, such as antisense RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs with processing defe

LOCALIZAÇÃO

CytoplasmNucleusNucleus, nucleolus

VIAS BIOLÓGICAS (5)
mRNA decay by 3' to 5' exoribonucleaseATF4 activates genes in response to endoplasmic reticulum stressKSRP (KHSRP) binds and destabilizes mRNAButyrate Response Factor 1 (BRF1) binds and destabilizes mRNATristetraprolin (TTP, ZFP36) binds and destabilizes mRNA
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 1C

A severe autosomal recessive neurodegenerative disease characterized by cerebellar and corpus callosum hypoplasia, abnormal myelination of the central nervous system, and spinal motor neuron disease. Affected individuals manifest failure to thrive, severe muscle weakness, spasticity and psychomotor retardation. Vision and hearing are impaired.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
60.2 TPM
Testículo
43.8 TPM
Ovário
40.4 TPM
Cervix Endocervix
38.1 TPM
Fallopian Tube
37.8 TPM
OUTRAS DOENÇAS (2)
pontocerebellar hypoplasia, type 1Cpontocerebellar hypoplasia type 1
HGNC:17035UniProt:Q96B26
DAB1Disabled homolog 1Candidate gene tested inAltamente restrito
FUNÇÃO

Signaling adapter of the reelin-mediated signaling pathway, which regulates the migration and differentiation of postmitotic neurons during brain development. Mediates intracellular transduction of Reelin signaling following reelin (RELN)-binding to its receptor: acts by docking proteins through its phosphotyrosine residues and PID domain

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Reelin signalling pathway
MECANISMO DE DOENÇA

Spinocerebellar ataxia 37

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA37 is an autosomal dominant form characterized by adult-onset of slowly progressive gait instability, frequent falls, and dysarthria associated with cerebellar atrophy on brain imaging.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
23.7 TPM
Cerebelo
19.4 TPM
Nervo tibial
7.7 TPM
Hipocampo
5.0 TPM
Brain Anterior cingulate cortex BA24
4.7 TPM
OUTRAS DOENÇAS (1)
spinocerebellar ataxia type 37
HGNC:2661UniProt:O75553
VLDLRVery low-density lipoprotein receptorCandidate gene tested inTolerante
FUNÇÃO

Multifunctional cell surface receptor that binds VLDL and transports it into cells by endocytosis and therefore plays an important role in energy metabolism. Also binds to a wide range of other molecules including Reelin/RELN or apolipoprotein E/APOE-containing ligands as well as clusterin/CLU (PubMed:24381170, PubMed:30873003). In the off-state of the pathway, forms homooligomers or heterooligomers with LRP8 (PubMed:30873003). Upon binding to ligands, homooligomers are rearranged to higher orde

LOCALIZAÇÃO

Cell membraneMembrane, clathrin-coated pit

VIAS BIOLÓGICAS (3)
VLDL clearanceVLDLR internalisation and degradationReelin signalling pathway
MECANISMO DE DOENÇA

Cerebellar ataxia, impaired intellectual development, and dysequilibrium syndrome 1

An autosomal recessive, congenital, non-progressive cerebellar ataxia associated with disturbed equilibrium, delayed ambulation, intellectual disability, cerebellar hypoplasia and mild cerebral gyral simplification. Additional features include short stature, strabismus, pes planus and, rarely, seizures.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
81.6 TPM
Artéria tibial
18.7 TPM
Coração - Átrio
18.7 TPM
Coração - Ventrículo esquerdo
16.5 TPM
Fallopian Tube
15.2 TPM
OUTRAS DOENÇAS (2)
cerebellar ataxia, intellectual disability, and dysequilibrium syndrome 1cerebellar ataxia, intellectual disability, and dysequilibrium
HGNC:12698UniProt:P98155
ALS2AlsinCandidate gene tested inTolerante
FUNÇÃO

May act as a GTPase regulator. Controls survival and growth of spinal motoneurons (By similarity)

LOCALIZAÇÃO

VIAS BIOLÓGICAS (2)
RAC1 GTPase cycleRAB GEFs exchange GTP for GDP on RABs
MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis 2

A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.

OUTRAS DOENÇAS (4)
infantile-onset ascending hereditary spastic paralysisjuvenile primary lateral sclerosisamyotrophic lateral sclerosis type 2, juvenilejuvenile amyotrophic lateral sclerosis
HGNC:443UniProt:Q96Q42
ALDH18A1Delta-1-pyrroline-5-carboxylate synthaseCandidate gene tested inTolerante
FUNÇÃO

Bifunctional enzyme that converts glutamate to glutamate 5-semialdehyde, an intermediate in the biosynthesis of proline, ornithine and arginine

LOCALIZAÇÃO

MitochondrionMitochondrion matrix

VIAS BIOLÓGICAS (1)
Mitochondrial protein degradation
MECANISMO DE DOENÇA

Cutis laxa, autosomal recessive, 3A

A syndrome characterized by facial dysmorphism with a progeroid appearance, large and late-closing fontanel, cutis laxa, joint hyperlaxity, athetoid movements and hyperreflexia, pre- and postnatal growth retardation, intellectual deficit, developmental delay, and ophthalmologic abnormalities.

OUTRAS DOENÇAS (6)
hereditary spastic paraplegia 9Aautosomal recessive complex spastic paraplegia type 9Bcutis laxa, autosomal dominant 3ALDH18A1-related de Barsy syndrome
HGNC:9722UniProt:P54886
GM2AGanglioside GM2 activatorCandidate gene tested inTolerante
FUNÇÃO

The large binding pocket can accommodate several single chain phospholipids and fatty acids, GM2A also exhibits some calcium-independent phospholipase activity (By similarity). Binds gangliosides and stimulates ganglioside GM2 degradation. It stimulates only the breakdown of ganglioside GM2 and glycolipid GA2 by beta-hexosaminidase A. It extracts single GM2 molecules from membranes and presents them in soluble form to beta-hexosaminidase A for cleavage of N-acetyl-D-galactosamine and conversion

LOCALIZAÇÃO

Lysosome

VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
MECANISMO DE DOENÇA

GM2-gangliosidosis AB

An autosomal recessive lysosomal storage disease marked by the accumulation of GM2 gangliosides in the neuronal cells. It is characterized by GM2 gangliosides accumulation in the presence of both normal hexosaminidase A and B.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
105.2 TPM
Vagina
90.7 TPM
Skin Not Sun Exposed Suprapubic
85.3 TPM
Skin Sun Exposed Lower leg
78.9 TPM
Esôfago - Mucosa
77.5 TPM
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (1)
Tay-Sachs disease AB variant
HGNC:4367UniProt:P17900
SLC9A1Sodium/hydrogen exchanger 1Candidate gene tested inAltamente restrito
FUNÇÃO

Electroneutral Na(+) /H(+) antiporter that extrudes Na(+) in exchange for external protons driven by the inward sodium ion chemical gradient, protecting cells from acidification that occurs from metabolism (PubMed:11350981, PubMed:11532004, PubMed:14680478, PubMed:15035633, PubMed:15677483, PubMed:17073455, PubMed:17493937, PubMed:22020933, PubMed:27650500, PubMed:32130622, PubMed:7110335, PubMed:7603840). Exchanges intracellular H(+) ions for extracellular Na(+) in 1:1 stoichiometry (By similar

LOCALIZAÇÃO

Cell membraneBasolateral cell membrane

VIAS BIOLÓGICAS (2)
Hyaluronan degradationSodium/Proton exchangers
MECANISMO DE DOENÇA

Lichtenstein-Knorr syndrome

An autosomal recessive neurologic disorder characterized by progressive cerebellar ataxia and severe progressive sensorineural hearing loss.

EXPRESSÃO TECIDUAL(Ubíquo)
Estômago
33.1 TPM
Glândula salivar
30.3 TPM
Cólon transverso
29.6 TPM
Pulmão
29.2 TPM
Cervix Ectocervix
28.0 TPM
OUTRAS DOENÇAS (1)
Lichtenstein-Knorr syndrome
HGNC:11071UniProt:P19634
UBAP1Ubiquitin-associated protein 1Candidate gene tested inAltamente restrito
FUNÇÃO

Component of the ESCRT-I complex, a regulator of vesicular trafficking process (PubMed:21757351, PubMed:22405001, PubMed:31203368). Binds to ubiquitinated cargo proteins and is required for the sorting of endocytic ubiquitinated cargos into multivesicular bodies (MVBs) (PubMed:21757351, PubMed:22405001). Plays a role in the proteasomal degradation of ubiquitinated cell-surface proteins, such as EGFR and BST2 (PubMed:22405001, PubMed:24284069, PubMed:31203368)

LOCALIZAÇÃO

Cytoplasm, cytosolEndosome

VIAS BIOLÓGICAS (5)
Late endosomal microautophagyHCMV Late EventsMembrane binding and targetting of GAG proteinsBudding and maturation of HIV virionEndosomal Sorting Complex Required For Transport (ESCRT)
MECANISMO DE DOENÇA

Spastic paraplegia 80, autosomal dominant

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
123.8 TPM
Esôfago - Mucosa
98.7 TPM
Cervix Ectocervix
97.6 TPM
Testículo
92.6 TPM
Artéria tibial
89.4 TPM
OUTRAS DOENÇAS (2)
spastic paraplegia 80, autosomal dominanthereditary spastic paraplegia 12
HGNC:12461UniProt:Q9NZ09
TECPR2Tectonin beta-propeller repeat-containing protein 2Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Probably plays a role as positive regulator of autophagy

LOCALIZAÇÃO

MECANISMO DE DOENÇA

Neuropathy, hereditary sensory and autonomic, 9, with developmental delay

A form of hereditary sensory and autonomic neuropathy, a genetically and clinically heterogeneous group of disorders characterized by degeneration of dorsal root and autonomic ganglion cells, and by sensory and/or autonomic abnormalities. HSAN9 is characterized by global developmental delay and intellectual disability, axial and appendicular hypotonia, dysarthria, and an abnormal gait that is often described as ataxic. Other features may include peripheral neuropathy, hyporeflexia, and autonomic dysfunction. Affected individuals also have dysmorphic features, thin corpus callosum on brain imaging, and episodes of central apnea, which may be fatal.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
25.5 TPM
Esôfago - Muscular
20.6 TPM
Sangue
19.8 TPM
Esôfago - Junção
19.7 TPM
Cerebelo
19.4 TPM
OUTRAS DOENÇAS (1)
hereditary spastic paraplegia 49
HGNC:19957UniProt:O15040
IGHMBP2DNA-binding protein SMUBP-2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

5' to 3' helicase that unwinds RNA and DNA duplexes in an ATP-dependent reaction (PubMed:19158098, PubMed:22999958, PubMed:30218034). Specific to 5'-phosphorylated single-stranded guanine-rich sequences (PubMed:22999958, PubMed:8349627). May play a role in RNA metabolism, ribosome biogenesis or initiation of translation (PubMed:19158098, PubMed:19299493). May play a role in regulation of transcription (By similarity). Interacts with tRNA-Tyr (PubMed:19299493)

LOCALIZAÇÃO

NucleusCytoplasmCell projection, axon

MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal recessive 1

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
48.4 TPM
Cólon sigmoide
33.5 TPM
Esôfago - Junção
31.9 TPM
Útero
29.7 TPM
Cerebelo
29.6 TPM
OUTRAS DOENÇAS (2)
autosomal recessive distal spinal muscular atrophy 1Charcot-Marie-Tooth disease axonal type 2S
HGNC:5542UniProt:P38935
WARS1Tryptophan--tRNA ligase, cytoplasmicDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Catalyzes the attachment of tryptophan to tRNA(Trp) in a two-step reaction: tryptophan is first activated by ATP to form Trp-AMP and then transferred to the acceptor end of the tRNA(Trp) Has no angiostatic activity Possesses an angiostatic activity but has no aminoacylation activity (PubMed:11773625, PubMed:11773626, PubMed:14630953). Inhibits fluid shear stress-activated responses of endothelial cells (PubMed:14630953). Regulates ERK, Akt, and eNOS activation pathways that are associated with a

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Cytosolic tRNA aminoacylation
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal dominant 9

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. HMND9 is characterized by juvenile onset of slowly progressive distal muscle weakness and atrophy affecting both the lower and upper limbs.

OUTRAS DOENÇAS (4)
neuronopathy, distal hereditary motor, type 9neurodevelopmental disorder with microcephaly and speech delay, with or without brain abnormalitiesautosomal recessive primary microcephalycomplex neurodevelopmental disorder
HGNC:12729UniProt:P23381
MTHFS5-formyltetrahydrofolate cyclo-ligaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Contributes to tetrahydrofolate metabolism. Helps regulate carbon flow through the folate-dependent one-carbon metabolic network that supplies carbon for the biosynthesis of purines, thymidine and amino acids. Catalyzes the irreversible conversion of 5-formyltetrahydrofolate (5-FTHF) to yield 5,10-methenyltetrahydrofolate

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Metabolism of folate and pterines
MECANISMO DE DOENÇA

Neurodevelopmental disorder with microcephaly, epilepsy, and hypomyelination

An autosomal recessive neurodevelopmental disorder with onset at birth or in early infancy, and characterized by microcephaly, short stature, severe global developmental delay, progressive spasticity, and epilepsy. Brain imaging shows delayed myelination, hypomyelination, enlarged ventricles, and cerebellar atrophy.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
99.8 TPM
Sangue
36.5 TPM
Rim - Córtex
28.1 TPM
Pituitária
26.3 TPM
Tireoide
22.0 TPM
OUTRAS DOENÇAS (1)
neurodevelopmental disorder with microcephaly, epilepsy, and hypomyelination
HGNC:7437UniProt:P49914
LETM1Mitochondrial proton/calcium exchanger proteinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays an important role in maintenance of mitochondrial morphology and in mediating either calcium or potassium/proton antiport (PubMed:18628306, PubMed:19797662, PubMed:24344246, PubMed:24898248, PubMed:29123128, PubMed:32139798, PubMed:36055214, PubMed:36321428). Mediates proton-dependent calcium efflux from mitochondrion (PubMed:19797662, PubMed:24344246, PubMed:29123128). Also functions as an electroneutral mitochondrial proton/potassium exchanger (PubMed:24898248, PubMed:36055214, PubMed:36

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Complex III assemblyMitochondrial calcium ion transport
MECANISMO DE DOENÇA

Neurodegeneration, childhood-onset, with multisystem involvement due to mitochondrial dysfunction

An autosomal recessive disorder characterized primarily by global developmental delay and variably impaired intellectual development with speech delay apparent from infancy. Affected individuals have hypotonia, poor feeding, poor overall growth, and respiratory distress early in life. Other features include visual impairment due to optic atrophy, sensorineural hearing loss, and neuromuscular abnormalities. Features suggestive of a mitochondrial disorder include cataracts, cardiomyopathy, diabetes mellitus, combined oxidative phosphorylation deficiency, and increased lactate. Some patients develop seizures, some have dysmorphic facial features, and some have non-specific abnormalities on brain imaging. Death in childhood may occur.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
38.5 TPM
Esôfago - Mucosa
37.7 TPM
Cerebelo
35.9 TPM
Cérebro - Hemisfério cerebelar
30.7 TPM
Linfócitos
30.6 TPM
OUTRAS DOENÇAS (2)
neurodegeneration, childhood-onset, with multisystem involvement due to mitochondrial dysfunctionWolf-Hirschhorn syndrome
HGNC:6556UniProt:O95202
SLC44A1Choline transporter-like protein 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Choline/H+ antiporter (PubMed:19357133, PubMed:23651124, PubMed:31855247, PubMed:33789160). Also acts as a high-affinity ethanolamine/H+ antiporter, regulating the supply of extracellular ethanolamine (Etn) for the CDP-Etn pathway, redistribute intracellular Etn and balance the CDP-Cho and CDP-Etn arms of the Kennedy pathway (PubMed:33789160). Involved in membrane synthesis and myelin production (PubMed:31855247)

LOCALIZAÇÃO

Cell membraneMitochondrion outer membrane

VIAS BIOLÓGICAS (2)
Synthesis of PCSLC-mediated bile acid transport
MECANISMO DE DOENÇA

Neurodegeneration, childhood-onset, with ataxia, tremor, optic atrophy, and cognitive decline

An autosomal recessive neurodegenerative disease characterized by progressive ataxia, tremor, cognitive decline, dysphagia, optic atrophy, dysarthria, as well as urinary and bowel incontinence. Brain MRI demonstrates cerebellar atrophy and leukoencephalopathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
110.2 TPM
Fibroblastos
61.2 TPM
Substância negra
37.4 TPM
Nervo tibial
33.3 TPM
Tireoide
31.2 TPM
OUTRAS DOENÇAS (1)
neurodegeneration, childhood-onset, with ataxia, tremor, optic atrophy, and cognitive decline
HGNC:HGNC:18798UniProt:Q8WWI5
FTH1Ferritin heavy chainDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Has ferroxidase activity (PubMed:9003196). Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation (PubMed:9003196). Also plays a role in delivery of iron to cells (By similarity). Mediates iron uptake in capsule cells of the developing kidney (By similarity). Delivery to lysosomes is mediated by the cargo receptor NCOA4 for autophagic degradation and release of iron (PubM

LOCALIZAÇÃO

CytoplasmLysosomeCytoplasmic vesicle, autophagosome

VIAS BIOLÓGICAS (2)
Scavenging by Class A ReceptorsNeutrophil degranulation
MECANISMO DE DOENÇA

Hemochromatosis 5

A disorder of iron metabolism characterized by iron overload. Excess iron is deposited in a variety of organs leading to their failure, and resulting in serious illnesses including cirrhosis, hepatomas, diabetes, cardiomyopathy, arthritis, and hypogonadotropic hypogonadism. Severe effects of the disease usually do not appear until after decades of progressive iron loading.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
4592.9 TPM
Nervo tibial
3095.0 TPM
Sangue
3042.7 TPM
Pulmão
2479.3 TPM
Tecido adiposo
2441.4 TPM
OUTRAS DOENÇAS (2)
neurodegeneration with brain iron accumulation 9hemochromatosis type 5
HGNC:3976UniProt:P02794
PANK2Pantothenate kinase 2, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial isoform that catalyzes the phosphorylation of pantothenate to generate 4'-phosphopantothenate in the first and rate-determining step of coenzyme A (CoA) synthesis (PubMed:15659606, PubMed:16272150, PubMed:17242360, PubMed:17825826). Required for angiogenic activity of umbilical vein of endothelial cells (HUVEC) (PubMed:30221726) Cytoplasmic isoform that catalyzes the phosphorylation of pantothenate to generate 4'-phosphopantothenate in the first and rate-determining step of coenzym

LOCALIZAÇÃO

MitochondrionMitochondrion intermembrane spaceNucleusCytoplasm

VIAS BIOLÓGICAS (1)
Coenzyme A biosynthesis
MECANISMO DE DOENÇA

Neurodegeneration with brain iron accumulation 1

Autosomal recessive neurodegenerative disorder associated with iron accumulation in the brain, primarily in the basal ganglia. Clinical manifestations include progressive muscle spasticity, hyperreflexia, muscle rigidity, dystonia, dysarthria, and intellectual deterioration which progresses to severe dementia over several years. It is clinically classified into classic, atypical, and intermediate phenotypes. Classic forms present with onset in first decade, rapid progression, loss of independent ambulation within 15 years. Atypical forms have onset in second decade, slow progression, maintenance of independent ambulation up to 40 years later. Intermediate forms manifest onset in first decade with slow progression or onset in second decade with rapid progression. Patients with early onset tend to also develop pigmentary retinopathy, whereas those with later onset tend to also have speech disorders and psychiatric features. All patients have the 'eye of the tiger' sign on brain MRI.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
18.2 TPM
Linfócitos
17.1 TPM
Cerebelo
15.5 TPM
Fibroblastos
15.4 TPM
Testículo
14.7 TPM
OUTRAS DOENÇAS (3)
pantothenate kinase-associated neurodegenerationatypical pantothenate kinase-associated neurodegenerationclassic pantothenate kinase-associated neurodegeneration
HGNC:15894UniProt:Q9BZ23
SLC31A1High affinity copper uptake protein 1Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Uniporter that mediates the transport of copper(1+) from the extracellular space to the cytoplasm, across the plasma membrane (PubMed:11734551, PubMed:16135512, PubMed:17525160, PubMed:19740744, PubMed:20451502, PubMed:20569931, PubMed:23658018) and delivers directly copper(1+) to specific chaperone such as ATOX1, via a copper(1+)- mediated transient interaction between the C-terminal domain and a copper(1+) chaperone, thus controlling intracellular copper(1+) levels (PubMed:11734551, PubMed:161

LOCALIZAÇÃO

Cell membraneEarly endosome membraneRecycling endosome membraneApical cell membraneLate endosome membraneBasolateral cell membrane

VIAS BIOLÓGICAS (1)
Metal ion SLC transporters
MECANISMO DE DOENÇA

Neurodegeneration and seizures due to copper transport defect

An autosomal recessive disorder of copper metabolism characterized by global developmental delay, seizures, cortical and cerebellar atrophy, and axial hypotonia. Death in infancy may occur.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
42.2 TPM
Glândula salivar
32.0 TPM
Fígado
32.0 TPM
Skin Sun Exposed Lower leg
31.2 TPM
Skin Not Sun Exposed Suprapubic
29.1 TPM
OUTRAS DOENÇAS (1)
neurodegeneration and seizures due to copper transport defect
HGNC:HGNC:11016UniProt:O15431
TWNKTwinkle mtDNA helicaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial helicase involved in mtDNA replication and repair (PubMed:12975372, PubMed:15167897, PubMed:17324440, PubMed:18039713, PubMed:18971204, PubMed:25824949, PubMed:26887820, PubMed:27226550). Might have a role in mtDNA repair (PubMed:27226550). Has DNA strand separation activity needed to form a processive replication fork for leading strand synthesis which is catalyzed by the formation of a replisome complex with POLG and mtSDB (PubMed:12975372, PubMed:15167897, PubMed:18039713, PubMe

LOCALIZAÇÃO

Mitochondrion matrix, mitochondrion nucleoidMitochondrion inner membrane

VIAS BIOLÓGICAS (3)
Strand-asynchronous mitochondrial DNA replicationMitochondrial protein degradationTranscriptional activation of mitochondrial biogenesis
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 3

A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
21.9 TPM
Testículo
20.3 TPM
Fibroblastos
14.6 TPM
Ovário
10.6 TPM
Útero
10.3 TPM
OUTRAS DOENÇAS (8)
mitochondrial DNA depletion syndrome 7 (hepatocerebral type)Perrault syndrome 5progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 3autosomal dominant progressive external ophthalmoplegia
HGNC:1160UniProt:Q96RR1
AARS2Alanine--tRNA ligase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction: alanine is first activated by ATP to form Ala-AMP and then transferred to the acceptor end of tRNA(Ala). Also edits incorrectly charged tRNA(Ala) via its editing domain (PubMed:21549344). In presence of high levels of lactate, also acts as a protein lactyltransferase that mediates lactylation of lysine residues in target proteins, such as CGAS (PubMed:39322678). Acts as an inhibitor of cGAS/STING signaling by catalyzing lac

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Mitochondrial tRNA aminoacylation
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 8

A mitochondrial disease characterized by a lethal infantile hypertrophic cardiomyopathy, generalized muscle dysfunction and some neurologic involvement. The liver is not affected.

OUTRAS DOENÇAS (4)
leukoencephalopathy, progressive, with ovarian failurecombined oxidative phosphorylation defect type 8leukoencephalopathy, diffuse hereditary, with spheroids 1obsolete ovarioleukodystrophy
HGNC:21022UniProt:Q5JTZ9
POLR3BDNA-directed RNA polymerase III subunit RPC2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic core component of RNA polymerase III (Pol III), a DNA-dependent RNA polymerase which synthesizes small non-coding RNAs using the four ribonucleoside triphosphates as substrates. Synthesizes 5S rRNA, snRNAs, tRNAs and miRNAs from at least 500 distinct genomic loci (PubMed:20413673, PubMed:33558766). Pol III-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol III is rec

LOCALIZAÇÃO

NucleusCytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Cytosolic sensors of pathogen-associated DNA
MECANISMO DE DOENÇA

Leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism

An autosomal recessive neurodegenerative disorder characterized by early childhood onset of cerebellar ataxia and mild intellectual disabilities associated with diffuse hypomyelination apparent on brain MRI. Variable features include oligodontia and/or hypogonadotropic hypogonadism.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
10.8 TPM
Skin Sun Exposed Lower leg
9.5 TPM
Esôfago - Mucosa
8.9 TPM
Skin Not Sun Exposed Suprapubic
8.5 TPM
Vagina
8.0 TPM
OUTRAS DOENÇAS (3)
hypomyelinating leukodystrophy 8 with or without oligodontia and-or hypogonadotropic hypogonadismCharcot-Marie-Tooth disease, demyelinating, IIA 1Iobsolete hypomyelination-hypogonadotropic hypogonadism-hypodontia syndrome
HGNC:30348UniProt:Q9NW08
GJC2Gap junction gamma-2 proteinDisease-causing germline mutation(s) inDesconhecido
FUNÇÃO

One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. May play a role in myelination in central and peripheral nervous systems

LOCALIZAÇÃO

Cell membraneCell junction, gap junction

VIAS BIOLÓGICAS (1)
Gap junction assembly
MECANISMO DE DOENÇA

Leukodystrophy, hypomyelinating, 2

An autosomal recessive hypomyelinating leukodystrophy with symptoms of Pelizaeus-Merzbacher disease. Clinically characterized by nystagmus, impaired motor development, ataxia, choreoathetotic movements, dysarthria, and progressive spasticity.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
83.4 TPM
Substância negra
19.4 TPM
Útero
15.3 TPM
Fallopian Tube
13.9 TPM
Hipocampo
13.8 TPM
OUTRAS DOENÇAS (4)
hypomyelinating leukodystrophy 2lymphatic malformation 3hereditary spastic paraplegia 44GJC2-related late-onset primary lymphedema
HGNC:17494UniProt:Q5T442
VPS11Vacuolar protein sorting-associated protein 11 homologDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays a role in vesicle-mediated protein trafficking to lysosomal compartments including the endocytic membrane transport and autophagic pathways. Believed to act as a core component of the putative HOPS and CORVET endosomal tethering complexes which are proposed to be involved in the Rab5-to-Rab7 endosome conversion probably implicating MON1A/B, and via binding SNAREs and SNARE complexes to mediate tethering and docking events during SNARE-mediated membrane fusion. The HOPS complex is proposed

LOCALIZAÇÃO

EndosomeLate endosome membraneLysosome membraneEarly endosomeCytoplasmic vesicleCytoplasmic vesicle, autophagosomeCytoplasmic vesicle, clathrin-coated vesicle

VIAS BIOLÓGICAS (1)
SARS-CoV-2 modulates autophagy
MECANISMO DE DOENÇA

Leukodystrophy, hypomyelinating, 12

An autosomal recessive neurologic disorder characterized by developmental delay, spasticity, truncal hypotonia, acquired microcephaly, intellectual disability with variable seizure disorder, accompanied by thin corpus callosum, paucity of white matter and delayed myelination.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
60.2 TPM
Cerebelo
59.7 TPM
Cervix Endocervix
59.0 TPM
Cérebro - Hemisfério cerebelar
58.2 TPM
Ovário
55.5 TPM
OUTRAS DOENÇAS (2)
hypomyelinating leukodystrophy 12dystonia 32
HGNC:14583UniProt:Q9H270
TMEM237Transmembrane protein 237Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the transition zone in primary cilia. Required for ciliogenesis

LOCALIZAÇÃO

MembraneCell projection, cilium

MECANISMO DE DOENÇA

Joubert syndrome 14

An autosomal recessive disorder characterized by severe intellectual disability, hypotonia, breathing abnormalities in infancy, and dysmorphic facial features. Neuroradiologically, it is characterized by cerebellar vermian hypoplasia/aplasia, thickened and reoriented superior cerebellar peduncles, and an abnormally large interpeduncular fossa, giving the appearance of a molar tooth on transaxial slices (molar tooth sign). Additional variable features include renal disease, abnormal eye movements, and postaxial polydactyly.

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
30.8 TPM
Skin Not Sun Exposed Suprapubic
24.6 TPM
Skin Sun Exposed Lower leg
22.7 TPM
Artéria tibial
20.4 TPM
Cérebro - Hemisfério cerebelar
18.9 TPM
OUTRAS DOENÇAS (5)
Joubert syndrome 14Meckel syndromeJoubert syndrome with oculorenal defectJoubert syndrome
HGNC:14432UniProt:Q96Q45
HEXABeta-hexosaminidase subunit alphaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Hydrolyzes the non-reducing end N-acetyl-D-hexosamine and/or sulfated N-acetyl-D-hexosamine of glycoconjugates, such as the oligosaccharide moieties from proteins and neutral glycolipids, or from certain mucopolysaccharides (PubMed:11707436, PubMed:8123671, PubMed:8672428, PubMed:9694901). The isozyme S is as active as the isozyme A on the anionic bis-sulfated glycans, the chondroitin-6-sulfate trisaccharide (C6S-3), and the dermatan sulfate pentasaccharide, and the sulfated glycosphingolipid SM

LOCALIZAÇÃO

Lysosome

VIAS BIOLÓGICAS (1)
Defective HEXA causes GM2G1 (Hyaluronan metabolism)
MECANISMO DE DOENÇA

GM2-gangliosidosis 1

An autosomal recessive lysosomal storage disease marked by the accumulation of GM2 gangliosides in the neuronal cells. It is characterized by GM2 gangliosides accumulation in the absence of HEXA activity, leading to neurodegeneration and, in the infantile form, death in early childhood. It exists in several forms: infantile (most common and most severe), juvenile and adult (late-onset).

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
43.9 TPM
Fibroblastos
39.7 TPM
Cervix Endocervix
36.7 TPM
Aorta
36.0 TPM
Pulmão
34.0 TPM
OUTRAS DOENÇAS (4)
Tay-Sachs diseaseTay-Sachs disease, b variant, infantile formTay-Sachs disease, B variant, adult formTay-Sachs disease, b variant, juvenile form
HGNC:4878UniProt:P06865
AARS1Alanine--tRNA ligase, cytoplasmicDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction: alanine is first activated by ATP to form Ala-AMP and then transferred to the acceptor end of tRNA(Ala) (PubMed:27622773, PubMed:27911835, PubMed:28493438, PubMed:33909043). Also edits incorrectly charged tRNA(Ala) via its editing domain (PubMed:27622773, PubMed:27911835, PubMed:28493438, PubMed:29273753). In presence of high levels of lactate, also acts as a protein lactyltransferase that mediates lactylation of lysine res

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Cytosolic tRNA aminoacylation
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2N

An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

OUTRAS DOENÇAS (6)
trichothiodystrophy 8, nonphotosensitiveleukoencephalopathy, hereditary diffuse, with spheroids 2developmental and epileptic encephalopathy, 29Charcot-Marie-Tooth disease axonal type 2N
HGNC:20UniProt:P49588
ATG7Ubiquitin-like modifier-activating enzyme ATG7Disease-causing germline mutation(s) inTolerante
FUNÇÃO

E1-like activating enzyme involved in the 2 ubiquitin-like systems required for cytoplasm to vacuole transport (Cvt) and autophagy. Activates ATG12 for its conjugation with ATG5 as well as the ATG8 family proteins for their conjugation with phosphatidylethanolamine. Both systems are needed for the ATG8 association to Cvt vesicles and autophagosomes membranes. Required for autophagic death induced by caspase-8 inhibition. Facilitates LC3-I lipidation with phosphatidylethanolamine to form LC3-II w

LOCALIZAÇÃO

CytoplasmPreautophagosomal structure

VIAS BIOLÓGICAS (3)
MacroautophagyAntigen processing: Ubiquitination & Proteasome degradationDengue Virus Attachment and Entry
MECANISMO DE DOENÇA

Spinocerebellar ataxia, autosomal recessive, 31

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR30 is characterized by global developmental delay, hypotonia, variably impaired intellectual and language development, ataxic gait, tremor, and dysarthria. Most affected individuals have optic atrophy. Additional features may include retinitis pigmentosa, sensorineural deafness, dysmorphic facial features, and possibly endocrine dysfunction.

OUTRAS DOENÇAS (1)
spinocerebellar ataxia, autosomal recessive 31
HGNC:HGNC:16935UniProt:O95352
GDAP2Ganglioside-induced differentiation-associated protein 2Disease-causing germline mutation(s) inTolerante
LOCALIZAÇÃO

MECANISMO DE DOENÇA

Spinocerebellar ataxia, autosomal recessive, 27

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR27 is a progressive disease characterized by gait difficulties, eye movement abnormalities, dysarthria, and difficulty writing. Some patients may lose independent ambulation. Additional features include spasticity of the lower limbs and cognitive impairment.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
5.4 TPM
Cervix Endocervix
4.7 TPM
Pulmão
4.5 TPM
Tireoide
4.4 TPM
Cervix Ectocervix
4.2 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (1)
spinocerebellar ataxia, autosomal recessive 27
HGNC:HGNC:18010UniProt:Q9NXN4
TDP2Tyrosyl-DNA phosphodiesterase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

DNA repair enzyme that can remove a variety of covalent adducts from DNA through hydrolysis of a 5'-phosphodiester bond, giving rise to DNA with a free 5' phosphate. Catalyzes the hydrolysis of dead-end complexes between DNA and the topoisomerase 2 (TOP2) active site tyrosine residue. The 5'-tyrosyl DNA phosphodiesterase activity can enable the repair of TOP2-induced DNA double-strand breaks/DSBs without the need for nuclease activity, creating a 'clean' DSB with 5'-phosphate termini that are re

LOCALIZAÇÃO

NucleusNucleus, PML bodyNucleus, nucleolusCytoplasm

VIAS BIOLÓGICAS (1)
Nonhomologous End-Joining (NHEJ)
MECANISMO DE DOENÇA

Spinocerebellar ataxia, autosomal recessive, 23

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR23 patients manifest epilepsy, intellectual disability, and gait ataxia.

EXPRESSÃO TECIDUAL(Ubíquo)
Intestino delgado
57.6 TPM
Cérebro - Hemisfério cerebelar
47.5 TPM
Cólon transverso
46.9 TPM
Próstata
44.4 TPM
Linfócitos
41.8 TPM
OUTRAS DOENÇAS (1)
spinocerebellar ataxia, autosomal recessive 23
HGNC:17768UniProt:O95551
ITPR1Inositol 1,4,5-trisphosphate-gated calcium channel ITPR1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Inositol 1,4,5-trisphosphate-gated calcium channel that, upon inositol 1,4,5-trisphosphate binding, mediates calcium release from the endoplasmic reticulum (ER) (PubMed:10620513, PubMed:27108797). Undergoes conformational changes upon ligand binding, suggesting structural flexibility that allows the channel to switch from a closed state, capable of interacting with its ligands such as 1,4,5-trisphosphate and calcium, to an open state, capable of transferring calcium ions across the ER membrane (

LOCALIZAÇÃO

Endoplasmic reticulum membraneCytoplasmic vesicle, secretory vesicle membraneCytoplasm, perinuclear region

VIAS BIOLÓGICAS (10)
Ion homeostasisRegulation of insulin secretionFCGR3A-mediated IL10 synthesisAntigen activates B Cell Receptor (BCR) leading to generation of second messengersCLEC7A (Dectin-1) induces NFAT activation
MECANISMO DE DOENÇA

Spinocerebellar ataxia 15

Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA15 is an autosomal dominant cerebellar ataxia (ADCA). It is very slow progressing form with a wide range of onset, ranging from childhood to adult. Most patients remain ambulatory.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
82.0 TPM
Cerebelo
76.2 TPM
Artéria coronária
59.8 TPM
Aorta
52.7 TPM
Fallopian Tube
47.8 TPM
OUTRAS DOENÇAS (3)
aniridia-cerebellar ataxia-intellectual disability syndromespinocerebellar ataxia type 29spinocerebellar ataxia type 15/16
HGNC:6180UniProt:Q14643
CHCHD10Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in the maintenance of mitochondrial organization and mitochondrial cristae structure

LOCALIZAÇÃO

Mitochondrion intermembrane space

VIAS BIOLÓGICAS (1)
Mitochondrial protein import
MECANISMO DE DOENÇA

Frontotemporal dementia and/or amyotrophic lateral sclerosis 2

A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis.

OUTRAS DOENÇAS (5)
lower motor neuron syndrome with late-adult onsetfrontotemporal dementia and/or amyotrophic lateral sclerosis 2autosomal dominant mitochondrial myopathy with exercise intoleranceamyotrophic lateral sclerosis
HGNC:15559UniProt:Q8WYQ3
ARAndrogen receptorDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues (PubMed:19022849). Transcription factor activity is modulated by bound coactivator and corepressor proteins like ZBTB7A that recruits NCOR1 and NCOR2 to the androgen response elements/ARE on target genes, negatively regulating androgen receptor signaling and androgen-induced cell proliferation (PubMed:20812024). Tran

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (6)
RUNX2 regulates osteoblast differentiationActivated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligandNuclear Receptor transcription pathwaySUMOylation of intracellular receptors
MECANISMO DE DOENÇA

Androgen insensitivity syndrome

An X-linked recessive form of pseudohermaphroditism due end-organ resistance to androgen. Affected males have female external genitalia, female breast development, blind vagina, absent uterus and female adnexa, and abdominal or inguinal testes, despite a normal 46,XY karyotype.

OUTRAS DOENÇAS (7)
Kennedy diseasehypospadias 1, X-linkedandrogen insensitivity syndromepartial androgen insensitivity syndrome
HGNC:644UniProt:P10275
SELENOIEthanolaminephosphotransferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Ethanolaminephosphotransferase that catalyzes the transfer of phosphoethanolamine (PE) from CDP-ethanolamine to lipid acceptors, the final step in the synthesis of PE via the 'Kennedy' pathway (PubMed:17132865, PubMed:28052917, PubMed:29500230). PE is the second most abundant phospholipid of membranes in mammals and is involved in various membrane-related cellular processes (PubMed:17132865). The enzyme is critical for the synthesis of several PE species and also catalyzes the synthesis of plasm

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Synthesis of PE
MECANISMO DE DOENÇA

Spastic paraplegia 81, autosomal recessive

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG81 is a complicated form characterized by white matter abnormalities, hypomyelination with progressive white matter loss, delayed motor development, progressive spasticity, and impaired intellectual development and speech delay. Additional features may include bifid uvula, microcephaly, seizures, and variable ocular anomalies.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
28.6 TPM
Skin Not Sun Exposed Suprapubic
23.1 TPM
Skin Sun Exposed Lower leg
22.1 TPM
Cerebelo
19.0 TPM
Linfócitos
17.6 TPM
OUTRAS DOENÇAS (2)
spastic paraplegia 81, autosomal recessiveautosomal recessive complex spastic paraplegia due to kennedy pathway dysfunction
HGNC:29361UniProt:Q9C0D9
NIPA1Magnesium transporter NIPA1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Acts as a Mg(2+) transporter. Can also transport other divalent cations such as Fe(2+), Sr(2+), Ba(2+), Zn(2+) and Co(2+) but to a much less extent than Mg(2+) (By similarity)

LOCALIZAÇÃO

Cell membraneEarly endosome

VIAS BIOLÓGICAS (1)
Miscellaneous transport and binding events
MECANISMO DE DOENÇA

Spastic paraplegia 6, autosomal dominant

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
66.2 TPM
Substância negra
32.7 TPM
Linfócitos
25.2 TPM
Hipotálamo
22.9 TPM
Brain Frontal Cortex BA9
22.2 TPM
OUTRAS DOENÇAS (2)
hereditary spastic paraplegia 6chromosome 15q11.2 deletion syndrome
HGNC:17043UniProt:Q7RTP0
KIF1AKinesin-like protein KIF1ADisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Kinesin motor with a plus-end-directed microtubule motor activity (By similarity). It is required for anterograde axonal transport of synaptic vesicle precursors (PubMed:33880452). Also required for neuronal dense core vesicles (DCVs) transport to the dendritic spines and axons. The interaction calcium-dependent with CALM1 increases vesicle motility and interaction with the scaffolding proteins PPFIA2 and TANC2 recruits DCVs to synaptic sites

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCell projection, neuron projectionCell projection, axonCytoplasm, perinuclear regionSynapseCytoplasmic vesicle, secretory vesicle, neuronal dense core vesicle membrane

VIAS BIOLÓGICAS (2)
KinesinsCOPI-dependent Golgi-to-ER retrograde traffic
MECANISMO DE DOENÇA

Spastic paraplegia 30A, autosomal dominant

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. Some SPG30A patients have a pure form of the disorder, limited to spastic paraplegia, whereas others may have a complicated form that includes additional features such as cognitive dysfunction, learning disabilities, peripheral sensorimotor neuropathy, urinary sphincter problems, and/or cerebellar atrophy. SPG30A is characterized by onset in the first or second decades of unsteady spastic gait and hyperreflexia of the lower limbs. Inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Tecido-específico)
Córtex cerebral
331.8 TPM
Brain Frontal Cortex BA9
301.8 TPM
Cerebelo
266.3 TPM
Brain Anterior cingulate cortex BA24
262.4 TPM
Cérebro - Hemisfério cerebelar
235.1 TPM
OUTRAS DOENÇAS (5)
spastic paraplegia 30b, autosomal recessiveneuropathy, hereditary sensory, type 2Cintellectual disability, autosomal dominant 9hereditary sensory and autonomic neuropathy type 2
HGNC:888UniProt:Q12756
KIF1CKinesin-like protein KIF1CDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Motor required for the retrograde transport of Golgi vesicles to the endoplasmic reticulum. Has a microtubule plus end-directed motility

LOCALIZAÇÃO

Cytoplasm, cytoskeleton

VIAS BIOLÓGICAS (2)
KinesinsCOPI-dependent Golgi-to-ER retrograde traffic
MECANISMO DE DOENÇA

Spastic ataxia 2, autosomal recessive

A neurologic disorder characterized by cerebellar ataxia, dysarthria, and variable spasticity of the lower limbs. Cognition is not affected.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
308.2 TPM
Brain Spinal cord cervical c-1
252.4 TPM
Substância negra
164.6 TPM
Artéria tibial
160.2 TPM
Aorta
151.4 TPM
OUTRAS DOENÇAS (1)
spastic ataxia 2
HGNC:6317UniProt:O43896
RPIARibose-5-phosphate isomeraseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the reversible conversion of ribose-5-phosphate to ribulose 5-phosphate and participates in the first step of the non-oxidative branch of the pentose phosphate pathway

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Pentose phosphate pathway
MECANISMO DE DOENÇA

Ribose 5-phosphate isomerase deficiency

An autosomal recessive inborn error of polyols metabolism characterized by highly elevated level of ribitol and arabitol in brain and body fluids. Clinical features include leukoencephalopathy, psychomotor retardation from early life, neurologic regression, and a mild sensorimotor neuropathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
69.7 TPM
Esôfago - Mucosa
35.0 TPM
Fibroblastos
34.2 TPM
Baço
33.5 TPM
Tecido adiposo
32.7 TPM
OUTRAS DOENÇAS (1)
ribose-5-P isomerase deficiency
HGNC:10297UniProt:P49247
PEX16Peroxisomal membrane protein PEX16Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for peroxisome membrane biogenesis. May play a role in early stages of peroxisome assembly. Can recruit other peroxisomal proteins, such as PEX3 and PMP34, to de novo peroxisomes derived from the endoplasmic reticulum (ER). May function as receptor for PEX3

LOCALIZAÇÃO

Peroxisome membrane

VIAS BIOLÓGICAS (1)
Class I peroxisomal membrane protein import
MECANISMO DE DOENÇA

Peroxisome biogenesis disorder complementation group 9

A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS).

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
31.4 TPM
Testículo
30.9 TPM
Tireoide
24.5 TPM
Nervo tibial
23.1 TPM
Brain Spinal cord cervical c-1
22.4 TPM
OUTRAS DOENÇAS (5)
peroxisome biogenesis disorder 8A (Zellweger)peroxisome biogenesis disorder 8BZellweger spectrum disordersobsolete neonatal adrenoleukodystrophy
HGNC:8857UniProt:Q9Y5Y5
PEX6Peroxisomal ATPase PEX6Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the PEX1-PEX6 AAA ATPase complex, a protein dislocase complex that mediates the ATP-dependent extraction of the PEX5 receptor from peroxisomal membranes, an essential step for PEX5 recycling (PubMed:16314507, PubMed:16854980, PubMed:21362118, PubMed:29884772). Specifically recognizes PEX5 monoubiquitinated at 'Cys-11', and pulls it out of the peroxisome lumen through the PEX2-PEX10-PEX12 retrotranslocation channel (PubMed:29884772). Extraction by the PEX1-PEX6 AAA ATPase complex is

LOCALIZAÇÃO

Cytoplasm, cytosolPeroxisome membraneCell projection, cilium, photoreceptor outer segment

VIAS BIOLÓGICAS (1)
Peroxisomal protein import
MECANISMO DE DOENÇA

Peroxisome biogenesis disorder complementation group 4

A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS).

EXPRESSÃO TECIDUAL(Ubíquo)
Fallopian Tube
66.8 TPM
Ovário
64.6 TPM
Cerebelo
61.1 TPM
Cérebro - Hemisfério cerebelar
58.5 TPM
Pituitária
55.1 TPM
OUTRAS DOENÇAS (6)
peroxisome biogenesis disorder 4Bperoxisome biogenesis disorder 4A (Zellweger)peroxisome biogenesis disorder due to PEX6 defectobsolete Heimler syndrome
HGNC:8859UniProt:Q13608
PEX12Peroxisome assembly protein 12Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of a retrotranslocation channel required for peroxisome organization by mediating export of the PEX5 receptor from peroxisomes to the cytosol, thereby promoting PEX5 recycling (PubMed:24662292, PubMed:9354782, PubMed:9632816). The retrotranslocation channel is composed of PEX2, PEX10 and PEX12; each subunit contributing transmembrane segments that coassemble into an open channel that specifically allows the passage of PEX5 through the peroxisomal membrane (By similarity). PEX12 also re

LOCALIZAÇÃO

Peroxisome membrane

VIAS BIOLÓGICAS (3)
Peroxisomal protein importE3 ubiquitin ligases ubiquitinate target proteinsClass I peroxisomal membrane protein import
MECANISMO DE DOENÇA

Peroxisome biogenesis disorder complementation group 3

A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS).

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
12.5 TPM
Fibroblastos
11.2 TPM
Pituitária
10.1 TPM
Glândula adrenal
9.2 TPM
Nervo tibial
9.2 TPM
OUTRAS DOENÇAS (4)
peroxisome biogenesis disorder type 3Bperoxisome biogenesis disorder 3A (Zellweger)Zellweger spectrum disordersobsolete neonatal adrenoleukodystrophy
HGNC:8854UniProt:O00623
PEX1Peroxisomal ATPase PEX1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the PEX1-PEX6 AAA ATPase complex, a protein dislocase complex that mediates the ATP-dependent extraction of the PEX5 receptor from peroxisomal membranes, an essential step for PEX5 recycling (PubMed:11439091, PubMed:16314507, PubMed:16854980, PubMed:21362118, PubMed:29884772). Specifically recognizes PEX5 monoubiquitinated at 'Cys-11', and pulls it out of the peroxisome lumen through the PEX2-PEX10-PEX12 retrotranslocation channel (PubMed:29884772). Extraction by the PEX1-PEX6 AAA A

LOCALIZAÇÃO

Cytoplasm, cytosolPeroxisome membrane

VIAS BIOLÓGICAS (1)
Peroxisomal protein import
MECANISMO DE DOENÇA

Peroxisome biogenesis disorder complementation group 1

A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS).

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
23.8 TPM
Nervo tibial
23.3 TPM
Cervix Endocervix
23.1 TPM
Tireoide
21.9 TPM
Cerebelo
21.8 TPM
OUTRAS DOENÇAS (6)
peroxisome biogenesis disorder 1Bperoxisome biogenesis disorder 1A (Zellweger)peroxisome biogenesis disorder due to PEX1 defectZellweger spectrum disorders
HGNC:8850UniProt:O43933
ZNHIT3Zinc finger HIT domain-containing protein 3Disease-causing germline mutation(s) inTolerante
LOCALIZAÇÃO

CytoplasmNucleus

MECANISMO DE DOENÇA

PEHO syndrome

An autosomal recessive syndrome characterized by progressive encephalopathy, lack of psychomotor development, severe intellectual disability, early onset epileptic seizures, optic nerve/cerebellar atrophy, pedal edema, and early death.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
40.4 TPM
Cérebro - Hemisfério cerebelar
37.9 TPM
Linfócitos
37.0 TPM
Cerebelo
32.3 TPM
Ovário
29.4 TPM
OUTRAS DOENÇAS (1)
PEHO syndrome
HGNC:12309UniProt:Q15649
AFG3L2Mitochondrial inner membrane m-AAA protease component AFG3L2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic component of the m-AAA protease, a protease that plays a key role in proteostasis of inner mitochondrial membrane proteins, and which is essential for axonal and neuron development (PubMed:19748354, PubMed:28396416, PubMed:29932645, PubMed:30683687, PubMed:31327635, PubMed:37917749, PubMed:38157846). AFG3L2 possesses both ATPase and protease activities: the ATPase activity is required to unfold substrates, threading them into the internal proteolytic cavity for hydrolysis into small pe

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Processing of SMDT1Mitochondrial protein degradation
MECANISMO DE DOENÇA

Spinocerebellar ataxia 28

Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA28 is an autosomal dominant cerebellar ataxia (ADCA) with a slow progressive course and no evidence of sensory involvement or cognitive impairment.

OUTRAS DOENÇAS (3)
optic atrophy 12spinocerebellar ataxia type 28spastic ataxia 5
HGNC:315UniProt:Q9Y4W6
VWA1von Willebrand factor A domain-containing protein 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Promotes matrix assembly (By similarity). Involved in the organization of skeletal muscles and in the formation of neuromuscular junctions (Probable)

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix, basement membrane

VIAS BIOLÓGICAS (2)
Post-translational protein phosphorylationRegulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
MECANISMO DE DOENÇA

Neuronopathy, hereditary motor, autosomal recessive 7

An autosomal recessive, neuromyopathic disorder that manifests in childhood or adulthood with proximal and distal muscle weakness predominantly of the lower limbs. Affected individuals have difficulty climbing stairs and problems standing on the heels. Most patients have foot deformities, and some may have leg muscle atrophy. Muscle biopsy and electrophysiologic studies are consistent with both a myopathic process and an axonal motor neuropathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
196.9 TPM
Próstata
99.7 TPM
Bladder
93.6 TPM
Esôfago - Muscular
81.6 TPM
Cólon sigmoide
79.6 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
neuronopathy, distal hereditary motor, autosomal recessive 7neuronopathy, distal hereditary motor, autosomal recessive 5
HGNC:30910UniProt:Q6PCB0
SLC5A7High affinity choline transporter 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

High-affinity Na(+)-coupled choline transmembrane symporter (PubMed:11027560, PubMed:11068039, PubMed:12237312, PubMed:12969261, PubMed:17005849, PubMed:23132865, PubMed:23141292, PubMed:27569547). Functions as an electrogenic, voltage-dependent transporter with variable charge/choline stoichiometry (PubMed:17005849). Choline uptake and choline-induced current is also Cl(-)-dependent where Cl(-) is likely a regulatory ion rather than cotransported ion (PubMed:11068039, PubMed:12237312, PubMed:17

LOCALIZAÇÃO

Presynaptic cell membraneCell projection, axonEarly endosome membraneCytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane

VIAS BIOLÓGICAS (2)
SLC-mediated bile acid transportAcetylcholine Neurotransmitter Release Cycle
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal dominant 7

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. HMND7 is characterized by onset in the second decade of progressive distal muscle wasting and weakness affecting the upper and lower limbs and resulting in walking difficulties and hand grip. There is significant muscle atrophy of the hands and lower limbs. The disorder is associated with vocal cord paresis due to involvement of the tenth cranial nerve.

EXPRESSÃO TECIDUAL(Baixa expressão)
Cólon sigmoide
3.2 TPM
Esôfago - Junção
1.8 TPM
Brain Putamen basal ganglia
1.6 TPM
Bladder
1.6 TPM
Esôfago - Muscular
1.5 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (3)
neuronopathy, distal hereditary motor, type 7Acongenital myasthenic syndrome 20distal hereditary motor neuropathy type 7
HGNC:14025UniProt:Q9GZV3
GARS1Glycine--tRNA ligaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the ATP-dependent ligation of glycine to the 3'-end of its cognate tRNA, via the formation of an aminoacyl-adenylate intermediate (Gly-AMP) (PubMed:17544401, PubMed:24898252, PubMed:28675565). Also produces diadenosine tetraphosphate (Ap4A), a universal pleiotropic signaling molecule needed for cell regulation pathways, by direct condensation of 2 ATPs. Thereby, may play a special role in Ap4A homeostasis (PubMed:19710017)

LOCALIZAÇÃO

CytoplasmCell projection, axonSecretedSecreted, extracellular exosomeMitochondrion

VIAS BIOLÓGICAS (1)
Cytosolic tRNA aminoacylation
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2D

A dominant axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

OUTRAS DOENÇAS (4)
neuronopathy, distal hereditary motor, type 5ACharcot-Marie-Tooth disease type 2Dspinal muscular atrophy, infantile, James typeneuronopathy, distal hereditary motor, type 5
HGNC:4162UniProt:P41250
COASYBifunctional coenzyme A synthaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Bifunctional enzyme that catalyzes the fourth step of the coenzyme A biosynthetic pathway, the adenylation of 4'-phosphopantetheine, and the fifth step, the phosphorylation of dephospho-CoA to CoA

LOCALIZAÇÃO

Cytoplasm, cytosolMitochondrion matrix

VIAS BIOLÓGICAS (1)
Coenzyme A biosynthesis
MECANISMO DE DOENÇA

Neurodegeneration with brain iron accumulation 6

A neurodegenerative disorder associated with iron accumulation in the brain, primarily in the basal ganglia. It is characterized by progressive motor and cognitive dysfunction beginning in childhood or young adulthood. Patients show extrapyramidal motor signs, such as spasticity, dystonia, and parkinsonism.

VIAS REACTOME (1)
OUTRAS DOENÇAS (2)
neurodegeneration with brain iron accumulation 6pontocerebellar hypoplasia, type 12
HGNC:29932UniProt:Q13057
FTLFerritin light chainDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a role in delivery of iron to cells. Mediates iron uptake in capsule cells of the developing kidney (By similarity). Delivery to lysosomes by the cargo receptor NCOA4 for autophagic degradation and release or iron (PubMed:24695223)

LOCALIZAÇÃO

Cytoplasmic vesicle, autophagosomeCytoplasmAutolysosome

VIAS BIOLÓGICAS (2)
Scavenging by Class A ReceptorsNeutrophil degranulation
MECANISMO DE DOENÇA

Hyperferritinemia with or without cataract

An autosomal dominant disease characterized by elevated level of ferritin in serum and tissues, and early-onset bilateral cataract. Cataracts may be subclinical in some patients.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
13154.6 TPM
Fibroblastos
12572.4 TPM
Pulmão
12131.1 TPM
Tecido adiposo
10012.1 TPM
Baço
9808.3 TPM
OUTRAS DOENÇAS (4)
neuroferritinopathyL-ferritin deficiencyhereditary hyperferritinemia with congenital cataractsobsolete genetic hyperferritinemia without iron overload
HGNC:3999UniProt:P02792
HEPACAMHepatic and glial cell adhesion moleculeDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in regulating cell motility and cell-matrix interactions. May inhibit cell growth through suppression of cell proliferation (PubMed:15885354, PubMed:15917256). In glia, associates and targets CLCN2 at astrocytic processes and myelinated fiber tracts where it may regulate transcellular chloride flux involved in neuron excitability (PubMed:22405205)

LOCALIZAÇÃO

CytoplasmCell membrane

MECANISMO DE DOENÇA

Megalencephalic leukoencephalopathy with subcortical cysts 2A

A neurodegenerative disorder characterized by infantile-onset macrocephaly and later onset of motor deterioration, with ataxia and spasticity, seizures, and cognitive decline of variable severity. The brain appears swollen on magnetic resonance imaging with white-matter abnormalities and subcortical cysts, in all stages of the disease.

EXPRESSÃO TECIDUAL(Tecido-específico)
Córtex cerebral
57.6 TPM
Brain Caudate basal ganglia
54.5 TPM
Brain Spinal cord cervical c-1
53.7 TPM
Brain Anterior cingulate cortex BA24
48.7 TPM
Cérebro - Amígdala
45.2 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (4)
megalencephalic leukoencephalopathy with subcortical cysts 2Amegalencephalic leukoencephalopathy with subcortical cysts 2B, remitting, with or without intellectual disabilitymegalencephalic leukoencephalopathy with subcortical cystsmacrocephaly-autism syndrome
HGNC:26361UniProt:Q14CZ8
SPG21MaspardinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May play a role as a negative regulatory factor in CD4-dependent T-cell activation

LOCALIZAÇÃO

Cytoplasm, cytosolMembraneEndosome membraneGolgi apparatus, trans-Golgi network membrane

MECANISMO DE DOENÇA

Spastic paraplegia 21, autosomal recessive

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG21 is associated with dementia and other central nervous system abnormalities. Subtle childhood abnormalities may be present, but the main features develop in early adulthood. The disease is slowly progressive, and cerebellar and extrapyramidal signs are also found in patients with advanced disease. Patients have a thin corpus callosum and white-matter abnormalities.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
75.6 TPM
Cervix Endocervix
73.4 TPM
Cervix Ectocervix
65.7 TPM
Tireoide
62.3 TPM
Linfócitos
61.7 TPM
OUTRAS DOENÇAS (1)
mast syndrome
HGNC:20373UniProt:Q9NZD8
CSF1RMacrophage colony-stimulating factor 1 receptorDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Tyrosine-protein kinase that acts as a cell-surface receptor for CSF1 and IL34 and plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. Promotes the release of pro-inflammatory chemokines in response to IL34 and CSF1, and thereby plays an important role in innate immunity and in inflammatory processes. Plays an important role in the regulation of osteoclast

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
Other interleukin signalingTranscriptional Regulation by VENTXSignaling by CSF1 (M-CSF) in myeloid cells
EXPRESSÃO TECIDUAL(Ubíquo)
Baço
206.9 TPM
Nervo tibial
49.7 TPM
Tecido adiposo
38.0 TPM
Pulmão
37.9 TPM
Adipose Visceral Omentum
34.3 TPM
OUTRAS DOENÇAS (3)
leukoencephalopathy, diffuse hereditary, with spheroids 1brain abnormalities, neurodegeneration, and dysosteosclerosisearly-onset calcifying leukoencephalopathy-skeletal dysplasia
HGNC:2433UniProt:P07333
EIF2B3Translation initiation factor eIF2B subunit gammaDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Acts as a component of the translation initiation factor 2B (eIF2B) complex, which catalyzes the exchange of GDP for GTP on the eukaryotic initiation factor 2 (eIF2) complex gamma subunit (PubMed:25858979, PubMed:27023709, PubMed:31048492). Its guanine nucleotide exchange factor activity is repressed when bound to eIF2 complex phosphorylated on the alpha subunit, thereby limiting the amount of methionyl-initiator methionine tRNA available to the ribosome and consequently global translation is re

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Recycling of eIF2:GDP
MECANISMO DE DOENÇA

Leukoencephalopathy with vanishing white matter 3

An autosomal recessive brain disease characterized by neurological features including progressive cerebellar ataxia, spasticity, and cognitive deficits. Brain imaging shows abnormal white matter that vanishes over time and is replaced by cerebrospinal fluid. Disease severity ranges from fatal infantile forms to adult forms without neurological deterioration. The disease is progressive with, in most individuals, additional episodes of rapid deterioration following febrile infections or minor head trauma. Death may occurs after a variable period after disease onset, usually following an episode of fever and coma. A subset of affected females with milder forms of the disease who survive to adolescence exhibit ovarian dysfunction. This variant of the disorder is called ovarioleukodystrophy.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
31.1 TPM
Nervo tibial
26.6 TPM
Fibroblastos
25.3 TPM
Testículo
24.9 TPM
Cervix Ectocervix
23.6 TPM
OUTRAS DOENÇAS (6)
leukoencephalopathy with vanishing white matter 3juvenile or adult CACH syndromeobsolete ovarioleukodystrophycongenital or early infantile CACH syndrome
HGNC:3259UniProt:Q9NR50
EIF2B2Translation initiation factor eIF2B subunit betaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Acts as a component of the translation initiation factor 2B (eIF2B) complex, which catalyzes the exchange of GDP for GTP on eukaryotic initiation factor 2 (eIF2) gamma subunit (PubMed:25858979, PubMed:27023709, PubMed:31048492). Its guanine nucleotide exchange factor activity is repressed when bound to eIF2 complex phosphorylated on the alpha subunit, thereby limiting the amount of methionyl-initiator methionine tRNA available to the ribosome and consequently global translation is repressed (Pub

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Recycling of eIF2:GDP
MECANISMO DE DOENÇA

Leukoencephalopathy with vanishing white matter 2

An autosomal recessive brain disease characterized by neurological features including progressive cerebellar ataxia, spasticity, and cognitive deficits. Brain imaging shows abnormal white matter that vanishes over time and is replaced by cerebrospinal fluid. Disease severity ranges from fatal infantile forms to adult forms without neurological deterioration. The disease is progressive with, in most individuals, additional episodes of rapid deterioration following febrile infections or minor head trauma. Death may occurs after a variable period after disease onset, usually following an episode of fever and coma. A subset of affected females with milder forms of the disease who survive to adolescence exhibit ovarian dysfunction. This variant of the disorder is called ovarioleukodystrophy.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
37.5 TPM
Artéria tibial
26.8 TPM
Testículo
25.3 TPM
Fibroblastos
25.2 TPM
Glândula adrenal
22.0 TPM
OUTRAS DOENÇAS (6)
leukoencephalopathy with vanishing white matter 2juvenile or adult CACH syndromelate infantile CACH syndromecongenital or early infantile CACH syndrome
HGNC:3258UniProt:P49770
EIF2B1Translation initiation factor eIF2B subunit alphaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Acts as a component of the translation initiation factor 2B (eIF2B) complex, which catalyzes the exchange of GDP for GTP on eukaryotic initiation factor 2 (eIF2) gamma subunit (PubMed:25858979, PubMed:27023709, PubMed:31048492). Its guanine nucleotide exchange factor activity is repressed when bound to eIF2 complex phosphorylated on the alpha subunit, thereby limiting the amount of methionyl-initiator methionine tRNA available to the ribosome and consequently global translation is repressed (Pub

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Recycling of eIF2:GDP
MECANISMO DE DOENÇA

Leukoencephalopathy with vanishing white matter 1

An autosomal recessive brain disease characterized by neurological features including progressive cerebellar ataxia, spasticity, and cognitive deficits. Brain imaging shows abnormal white matter that vanishes over time and is replaced by cerebrospinal fluid. Disease severity ranges from fatal infantile forms to adult forms without neurological deterioration. The disease is progressive with, in most individuals, additional episodes of rapid deterioration following febrile infections or minor head trauma. Death may occurs after a variable period after disease onset, usually following an episode of fever and coma. A subset of affected females with milder forms of the disease who survive to adolescence exhibit ovarian dysfunction. This variant of the disorder is called ovarioleukodystrophy.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Útero
67.5 TPM
Cervix Endocervix
63.4 TPM
Linfócitos
62.4 TPM
Cervix Ectocervix
61.6 TPM
Ovário
59.6 TPM
OUTRAS DOENÇAS (5)
leukoencephalopathy with vanishing white matter 1juvenile or adult CACH syndromecongenital or early infantile CACH syndromelate infantile CACH syndrome
HGNC:3257UniProt:Q14232
SLC35B2Adenosine 3'-phospho 5'-phosphosulfate transporter 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Probably functions as a 3'-phosphoadenylyl sulfate:adenosine 3',5'-bisphosphate antiporter at the Golgi membranes. Mediates the transport from the cytosol into the lumen of the Golgi of 3'-phosphoadenylyl sulfate/adenosine 3'-phospho 5'-phosphosulfate (PAPS), a universal sulfuryl donor for sulfation events that take place in that compartment

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (2)
Transport of nucleotide sugarsTransport and metabolism of PAPS
MECANISMO DE DOENÇA

Leukodystrophy, hypomyelinating, 26, with chondrodysplasia

A form of hypomyelinating leukodystrophy, a group of heterogeneous disorders characterized by persistent deficit of myelin observed on brain imaging. HLD26 is an autosomal recessive form characterized by severe psychomotor delay, limited or absent speech, abnormal development of brain white matter, corpus callosum hypoplasia, and cerebral atrophy. Other features include pre- and postnatal growth retardation, chondrodysplasia, and early-onset scoliosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
119.2 TPM
Linfócitos
68.9 TPM
Nervo tibial
55.0 TPM
Útero
53.9 TPM
Cervix Endocervix
52.3 TPM
OUTRAS DOENÇAS (1)
leukodystrophy, hypomyelinating, 26, with chondrodysplasia
HGNC:HGNC:16872UniProt:Q8TB61
CSPP1Centrosome and spindle pole-associated protein 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May play a role in cell-cycle-dependent microtubule organization

LOCALIZAÇÃO

Cytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, spindleCytoplasm, cytoskeleton, spindle poleCell projection, cilium

MECANISMO DE DOENÇA

Joubert syndrome 21

A disorder presenting with cerebellar ataxia, oculomotor apraxia, hypotonia, neonatal breathing abnormalities and psychomotor delay. Neuroradiologically, it is characterized by cerebellar vermian hypoplasia/aplasia, thickened and reoriented superior cerebellar peduncles, and an abnormally large interpeduncular fossa, giving the appearance of a molar tooth on transaxial slices (molar tooth sign). Additional variable features include retinal dystrophy, renal disease, liver fibrosis, and polydactyly.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
24.0 TPM
Cérebro - Hemisfério cerebelar
10.9 TPM
Fallopian Tube
9.5 TPM
Cervix Endocervix
9.5 TPM
Ovário
9.4 TPM
OUTRAS DOENÇAS (4)
Joubert syndrome 21Joubert syndromeJoubert syndrome with Jeune asphyxiating thoracic dystrophyMeckel syndrome
HGNC:26193UniProt:Q1MSJ5
CEP41Centrosomal protein of 41 kDaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Required during ciliogenesis for tubulin glutamylation in cilium. Probably acts by participating in the transport of TTLL6, a tubulin polyglutamylase, between the basal body and the cilium

LOCALIZAÇÃO

Cytoplasm, cytoskeleton, microtubule organizing center, centrosomeCell projection, ciliumCytoplasm, cytoskeleton, cilium basal body

VIAS BIOLÓGICAS (7)
Recruitment of mitotic centrosome proteins and complexesLoss of proteins required for interphase microtubule organization from the centrosomeLoss of Nlp from mitotic centrosomesRegulation of PLK1 Activity at G2/M TransitionAURKA Activation by TPX2
MECANISMO DE DOENÇA

Joubert syndrome 15

An autosomal recessive disorder presenting with cerebellar ataxia, oculomotor apraxia, hypotonia, neonatal breathing abnormalities and psychomotor delay. Neuroradiologically, it is characterized by cerebellar vermian hypoplasia/aplasia, thickened and reoriented superior cerebellar peduncles, and an abnormally large interpeduncular fossa, giving the appearance of a molar tooth on transaxial slices (molar tooth sign). Additional variable features include retinal dystrophy, renal disease, liver fibrosis and polydactyly.

OUTRAS DOENÇAS (3)
Joubert syndrome 15Joubert syndromeJoubert syndrome with ocular defect
HGNC:12370UniProt:Q9BYV8

Variantes genéticas (ClinVar)

258 variantes patogênicas registradas no ClinVar.

🧬 DARS1: NM_001349.4(DARS1):c.124+82G>A ()
🧬 DARS1: NM_001349.4(DARS1):c.67-5del ()
🧬 DARS1: NM_001349.4(DARS1):c.735C>G (p.Tyr245Ter) ()
🧬 DARS1: GRCh37/hg19 2q21.2-23.2(chr2:134589311-149951291)x3 ()
🧬 DARS1: NM_001349.4(DARS1):c.821C>G (p.Ala274Gly) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

162 vias biológicas associadas aos genes desta condição.

Selenoamino acid metabolism Cytosolic tRNA aminoacylation Transcriptional and post-translational regulation of MITF-M expression and activity Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA Regulation of PTEN gene transcription Mitochondrial translation termination Respiratory electron transport Complex I biogenesis Mitochondrial protein degradation Josephin domain DUBs FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes ALKBH3 mediated reversal of alkylation damage Formation of ATP by chemiosmotic coupling Cristae formation Negative regulation of TCF-dependent signaling by DVL-interacting proteins Aspartate and asparagine metabolism Amyloid fiber formation MyD88:MAL(TIRAP) cascade initiated on plasma membrane Dengue Virus Attachment and Entry Malate-aspartate shuttle Replacement of protamines by nucleosomes in the male pronucleus Defective SLC5A1 causes congenital glucose/galactose malabsorption (GGM) Toll-like Receptor Cascades RHO GTPases Activate Formins Signaling by Rho GTPases RHO GTPase Effectors Toll Like Receptor 4 (TLR4) Cascade snRNP Assembly SARS-CoV-2 modulates host translation machinery Hedgehog 'off' state Anchoring of the basal body to the plasma membrane G alpha (q) signalling events Class C/3 (Metabotropic glutamate/pheromone receptors) Neurexins and neuroligins Sensory perception of sweet, bitter, and umami (glutamate) taste SLBP independent Processing of Histone Pre-mRNAs RNA Polymerase II Transcription Termination SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs Regulation by TREX1 IRF3-mediated induction of type I IFN ABC-family proteins mediated transport Defective CFTR causes cystic fibrosis AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) Mitochondrial protein import Mitochondrial iron-sulfur cluster biogenesis Maturation of TCA enzymes and regulation of TCA cycle Complex III assembly CPT1B transfers PALM to CAR CPT1A transfers PALM to CAR VLDL assembly Chylomicron assembly LDL remodeling Cytosolic sensors of pathogen-associated DNA RNA Polymerase III Chain Elongation RNA Polymerase III Transcription Termination RNA Polymerase III Abortive And Retractive Initiation RNA Polymerase III Transcription Initiation From Type 1 Promoter RNA Polymerase III Transcription Initiation From Type 2 Promoter RNA Polymerase III Transcription Initiation From Type 3 Promoter ATF4 activates genes in response to endoplasmic reticulum stress mRNA decay by 3' to 5' exoribonuclease Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA KSRP (KHSRP) binds and destabilizes mRNA Major pathway of rRNA processing in the nucleolus and cytosol Nuclear RNA decay Peptide chain elongation Uptake and function of diphtheria toxin Synthesis of diphthamide-EEF2 Neutrophil degranulation Protein methylation Alanine metabolism Nuclear signaling by ERBB4 Chaperone Mediated Autophagy Nuclear Envelope Breakdown Initiation of Nuclear Envelope (NE) Reformation Reelin signalling pathway VLDLR internalisation and degradation VLDL clearance RAB GEFs exchange GTP for GDP on RABs RAC1 GTPase cycle Glutamate and glutamine metabolism Glycosphingolipid catabolism Hyaluronan degradation Sodium/Proton exchangers Budding and maturation of HIV virion Membrane binding and targetting of GAG proteins Endosomal Sorting Complex Required For Transport (ESCRT) HCMV Late Events Late endosomal microautophagy Metabolism of folate and pterines Mitochondrial calcium ion transport RHOG GTPase cycle Synthesis of PC Choline catabolism SLC-mediated bile acid transport Scavenging by Class A Receptors Golgi Associated Vesicle Biogenesis Iron uptake and transport Coenzyme A biosynthesis Metal ion SLC transporters Transcriptional activation of mitochondrial biogenesis Strand-asynchronous mitochondrial DNA replication Mitochondrial tRNA aminoacylation Gap junction assembly SARS-CoV-2 modulates autophagy Keratan sulfate degradation CS/DS degradation Defective HEXA causes GM2G1 (Hyaluronan metabolism) Macroautophagy Signaling by BRAF and RAF1 fusions Antigen processing: Ubiquitination & Proteasome degradation Nonhomologous End-Joining (NHEJ) PLC beta mediated events Effects of PIP2 hydrolysis Elevation of cytosolic Ca2+ levels DAG and IP3 signaling Role of phospholipids in phagocytosis FCERI mediated Ca+2 mobilization Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Ca2+ pathway cGMP effects Regulation of insulin secretion VEGFR2 mediated cell proliferation Ion homeostasis CLEC7A (Dectin-1) induces NFAT activation FCGR3A-mediated IL10 synthesis Antigen activates B Cell Receptor (BCR) leading to generation of second messengers HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 Ub-specific processing proteases RUNX2 regulates osteoblast differentiation Synthesis of PE Miscellaneous transport and binding events COPI-dependent Golgi-to-ER retrograde traffic Kinesins RPIA deficiency: failed conversion of R5P to RU5P RPIA deficiency: failed conversion of RU5P to R5P Pentose phosphate pathway Class I peroxisomal membrane protein import Peroxisomal protein import E3 ubiquitin ligases ubiquitinate target proteins Processing of SMDT1 Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Post-translational protein phosphorylation Acetylcholine Neurotransmitter Release Cycle Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A) Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A) Other interleukin signaling Transcriptional Regulation by VENTX Signaling by CSF1 (M-CSF) in myeloid cells Recycling of eIF2:GDP Transport and metabolism of PAPS Transport of nucleotide sugars Regulation of PLK1 Activity at G2/M Transition Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes AURKA Activation by TPX2

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 31
2Fase 23
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 5 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença neurodegenerativa genética

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

0 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
51 papers (10 anos)
#1

Spatially resolved lipids in a mouse brain model of globoid cell leukodystrophy via IR-MALDESI MSI and parallel reaction monitoring MSI.

Analytical and bioanalytical chemistry2026 Apr

Globoid cell leukodystrophy (GLD) is a genetic neurodegenerative disease caused by mutations in galactosylceramide β-galactosidase (GALC) that results in the accumulation of the cytotoxic sphingolipid, psychosine. As psychosine is a biomarker specific to GLD, identifying the most afflicted regions of the nervous system can assist in better understanding the disease mechanism. Infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) mass spectrometry imaging (MSI) and parallel reaction monitoring were utilized to elucidate the spatial distribution of the psychosine analyte and confirm the identity of the ion in a sagittal section of a GALC-deficient mouse brain. The presence of the psychosine was increased in specific anatomical regions of the brain responsible for the bodily functions that are impaired by GLD (cerebellum and brain stem). Several electrospray solvent additives (dopants) have enhanced the detection of various analyte types but with little success in enhancing the detection of sphingolipids. This study investigates the usefulness of ammonium fluoride electrospray doping in the positive ion mode for lipidomic IR-MALDESI MSI analysis.

#2

Short Review on Currently Used Sample Preparation and Determination Methods of Risdiplam.

Journal of separation science2025 May

Risdiplam is a new therapeutic agent developed to treat spinal muscular atrophy (SMA), a genetic neurodegenerative disease caused by mutations in the SMN1 gene. Unlike previous invasive therapies, risdiplam offers the advantage of oral administration, significantly improving patient comfort and accessibility. The review provides information on an SMA historical overview, breakthrough therapies of the development, and design of the methods used to treat SMA. We then focus on its structure and physicochemical properties. The analysis of risdiplam concentrates on developing improved analytical methods for the precise quantification of risdiplam and its metabolites by high-performance liquid chromatography with mass spectrometry in biological samples using octadecyl stationary phases. For sample preparation, only the protein precipitation method was used. Challenges associated with the risdiplam analytics include developing a highly sensitive and selective method in biological matrices and dealing with potential interferences from the biological matrix. Future research should focus on improving analytical methods, investigating metabolite activity, and expanding our knowledge of its long-term effects.

#3

Episodic headaches and cognitive decline: uncovering neuronal intranuclear inclusion disease in a young patient.

BMJ case reports2025 Jan 02

A male in his 20s presented with episodic headache and subsequently developed episodic unilateral weakness, dysphasia and encephalopathy. These paroxysmal episodes persisted over time with the development of background cognitive impairment and neuropsychiatric symptoms. MRI surveillance demonstrated progressive T2 hyperintensity with focal cortical oedema correlating to symptoms observed during clinical episodes.Genetic testing for hemiplegic migraine, mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes along with exome sequencing and high-density microarray did not reveal a cause for the clinical phenotype. The diagnosis of neuronal intranuclear inclusion disease (NIID) was confirmed by the detection of large guanine-guanine-cytosine repeat expansion in the Notch 2 N-terminal-like C gene using long-read nanopore sequencing.NIID is a genetic neurodegenerative disease, more common in Asian populations. It can present with a varied neurological phenotype, including an episodic event type that can mimic hemiplegic migraine and encephalopathy. This case report highlights the importance of considering NIID in cases of paroxysmal headache and encephalopathy.

#4

Assessment of Fine Motor Abilities Among Children with Spinal Muscular Atrophy Treated with Nusinersen Using a New Touchscreen Application: A Pilot Study.

Children (Basel, Switzerland)2025 Oct 12

Background/Objectives: Spinal Muscular Atrophy (SMA) is a genetic neurodegenerative disease characterized by severe muscle weakness and atrophy. Advances in disease-modifying therapies have dramatically changed the natural history of SMA and the outcome measures that are used to assess the clinical response to therapy. Standard assessment methods for SMA are limited in their ability to detect minor changes in fine motor abilities and in patients' daily functions. The aim of this pilot study was to evaluate the feasibility and preliminary use of the Touchscreen-Assessment Tool (TATOO) alongside standardized tools to detect changes in upper extremity motor function among individuals with SMA receiving nusinersen therapy. Methods: Thirteen individuals with genetically-confirmed SMA, aged 6-23 years, eight with SMA type 2, and five with SMA type 3, participated. The patients continued the maintenance dosing of nusinersen during the study period. They were evaluated at the onset of the study, then twice more at intervals at least six months apart. Upper extremity functional assessments were performed via the TATOO and standardized tools: the Hand Grip Dynamometer (HGD), Pinch Dynamometer (PD), Revised Upper Limb Module (RULM), and Nine-Hole Peg Test (NHPT). Results: Significant changes in fine motor function were detected using the TATOO together with other standardized tools. Participants demonstrated notable improvements in hand grip strength and fine motor performance, as measured by the NHPT. The RULM results were not statistically significant for the total study group, particularly in ambulatory patients with SMA type 3. TATOO provided detailed metrics, and revealed enhancements in accuracy and speed across various tasks. However, given the small sample size, the lack of a control group, and the lack of baseline assessment before receiving therapy, these findings should be considered preliminary and exploratory. Conclusions: The findings suggest that the TATOO, alongside traditional assessment tools, offers a sensitive measure of fine motor function changes in patients with SMA. This study highlights the potential of touchscreen-based assessments to address gaps in current outcome measures and emphasizes the need for larger, multicenter studies that will include pre-treatment, baseline, and control data.

#5

Poly ADP-ribose signaling is dysregulated in Huntington disease.

Proceedings of the National Academy of Sciences of the United States of America2024 Oct

Huntington disease (HD) is a genetic neurodegenerative disease caused by cytosine, adenine, guanine (CAG) expansion in the Huntingtin (HTT) gene, translating to an expanded polyglutamine tract in the HTT protein. Age at disease onset correlates to CAG repeat length but varies by decades between individuals with identical repeat lengths. Genome-wide association studies link HD modification to DNA repair and mitochondrial health pathways. Clinical studies show elevated DNA damage in HD, even at the premanifest stage. A major DNA repair node influencing neurodegenerative disease is the PARP pathway. Accumulation of poly adenosine diphosphate (ADP)-ribose (PAR) has been implicated in Alzheimer and Parkinson diseases, as well as cerebellar ataxia. We report that HD mutation carriers have lower cerebrospinal fluid PAR levels than healthy controls, starting at the premanifest stage. Human HD induced pluripotent stem cell-derived neurons and patient-derived fibroblasts have diminished PAR response in the context of elevated DNA damage. We have defined a PAR-binding motif in HTT, detected HTT complexed with PARylated proteins in human cells during stress, and localized HTT to mitotic chromosomes upon inhibition of PAR degradation. Direct HTT PAR binding was measured by fluorescence polarization and visualized by atomic force microscopy at the single molecule level. While wild-type and mutant HTT did not differ in their PAR binding ability, purified wild-type HTT protein increased in vitro PARP1 activity while mutant HTT did not. These results provide insight into an early molecular mechanism of HD, suggesting possible targets for the design of early preventive therapies.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC2 artigos no totalmostrando 50

2026

Spatially resolved lipids in a mouse brain model of globoid cell leukodystrophy via IR-MALDESI MSI and parallel reaction monitoring MSI.

Analytical and bioanalytical chemistry
2025

Assessment of Fine Motor Abilities Among Children with Spinal Muscular Atrophy Treated with Nusinersen Using a New Touchscreen Application: A Pilot Study.

Children (Basel, Switzerland)
2025

Short Review on Currently Used Sample Preparation and Determination Methods of Risdiplam.

Journal of separation science
2025

Episodic headaches and cognitive decline: uncovering neuronal intranuclear inclusion disease in a young patient.

BMJ case reports
2024

SMN2 Copy Number Association with Spinal Muscular Atrophy Severity: Insights from Colombian Patients.

Journal of clinical medicine
2024

Poly ADP-ribose signaling is dysregulated in Huntington disease.

Proceedings of the National Academy of Sciences of the United States of America
2024

Inflammation and Huntington's disease - a neglected therapeutic target?

Expert opinion on investigational drugs
2024

Lipid droplet accumulation in Wdr45-deficient cells caused by impairment of chaperone-mediated autophagic degradation of Fasn.

Lipids in health and disease
2024

Infrequent patterns in cerebrospinal fluid isofocusing test: Clinical significance and contribution of IgG index and Reiber diagram to their interpretation.

Multiple sclerosis and related disorders
2024

A case report of fatal familial insomnia with cerebrospinal fluid leukocytosis during the COVID-19 epidemic and review of the literature.

Prion
2023

Pain in Children and Adolescents with Spinal Muscular Atrophy: A Longitudinal Study from a Patient Registry.

Children (Basel, Switzerland)
2023

Dysregulation of Human Juvenile Huntington's Disease Brain Proteomes in Cortex and Putamen Involves Mitochondrial and Neuropeptide Systems.

Journal of Huntington's disease
2024

cGAS-STING signalling regulates microglial chemotaxis in genome instability.

Nucleic acids research
2023

High-sensitive cardiac troponin I (hs-cTnI) concentrations in newborns diagnosed with spinal muscular atrophy.

Frontiers in pediatrics
2024

Altered anterograde axonal transport of mitochondria in cultured striatal neurons of a knock-in mouse model of Huntington's disease.

Biochemical and biophysical research communications
2023

Language disorders in patients with striatal lesions: Deciphering the role of the striatum in language performance.

Cortex; a journal devoted to the study of the nervous system and behavior
2023

[Gene Therapy for Huntington Disease].

Fortschritte der Neurologie-Psychiatrie
2022

Dopa-Responsive Dystonia: An Early Presentation of Ataxia-Telangiectasia.

Annals of Indian Academy of Neurology
2023

Quality of life, health-related quality of life, and associated factors in Huntington's disease: a systematic review.

Journal of neurology
2022

Health related quality of life, service utilization and costs for patients with Huntington's disease in Norway.

BMC health services research
2022

Neuroprotective Effects of σ2R/TMEM97 Receptor Modulators in the Neuronal Model of Huntington's Disease.

ACS chemical neuroscience
2024

Validation of Neuromyotype: a smart keyboard for the evaluation of spinal muscular atrophy patients.

Neurologia
2022

Beyond the CAG triplet number: exploring potential predictors of delayed age of onset in Huntington's disease.

Journal of neurology
2022

Mutant Huntingtin Protein Interaction Map Implicates Dysregulation of Multiple Cellular Pathways in Neurodegeneration of Huntington's Disease.

Journal of Huntington's disease
2022

Temporal Characterization of Behavioral and Hippocampal Dysfunction in the YAC128 Mouse Model of Huntington's Disease.

Biomedicines
2022

A resting-state fMRI pattern of spinocerebellar ataxia type 3 and comparison with 18F-FDG PET.

NeuroImage. Clinical
2022

Spinocerebellar ataxia type 3: response to levodopa infusion in two cases.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2022

A Rare Neonatal Intramedullary Immature Teratoma Undiagnosed in utero: A Case Report.

Pediatric neurosurgery
2021

Huntington's Disease in Israel: A Population-Based Study Using 20 Years of Routinely-Collected Healthcare Data.

Journal of Huntington's disease
2021

Transcriptomic and Metabolic Network Analysis of Metabolic Reprogramming and IGF-1 Modulation in SCA3 Transgenic Mice.

International journal of molecular sciences
2021

Brain hypometabolism in rare genetic neurodegenerative disease: Niemann-Pick disease type C, spinocerebellar ataxia and Huntington disease assessed by FDG PET.

Asia Oceania journal of nuclear medicine & biology
2021

The nucleoplasmic interactions among Lamin A/C-pRB-LAP2α-E2F1 are modulated by dexamethasone.

Scientific reports
2021

A novel pathogenic variant in the 3' end of the AGTPBP1 gene gives rise to neurodegeneration without cerebellar atrophy: an expansion of the disease phenotype?

Neurogenetics
2020

Impact of a national population-based carrier-screening program on spinal muscular atrophy births.

Neuromuscular disorders : NMD
2021

Neuropsychiatric comorbidities in Huntington's and Parkinson's Disease: A United States claims database analysis.

Annals of clinical and translational neurology
2020

A Comprehensive Transcriptome Analysis Identifies FXN and BDNF as Novel Targets of miRNAs in Friedreich's Ataxia Patients.

Molecular neurobiology
2020

SUMOylation Prevents Huntingtin Fibrillization and Localization onto Lipid Membranes.

ACS chemical neuroscience
2019

Self-association of human beta-galactocerebrosidase: Dependence on pH, salt, and surfactant.

PloS one
2019

A Deep Learning-Based Approach for Gait Analysis in Huntington Disease.

Studies in health technology and informatics
2019

Specific patterns of brain alterations underlie distinct clinical profiles in Huntington's disease.

NeuroImage. Clinical
2019

Inhibition of the IGF-1-PI3K-Akt-mTORC2 pathway in lipid rafts increases neuronal vulnerability in a genetic lysosomal glycosphingolipidosis.

Disease models & mechanisms
2018

Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease.

Scientific reports
2018

The role of oxidative stress in Friedreich's ataxia.

FEBS letters
2017

Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease.

Molecular therapy : the journal of the American Society of Gene Therapy
2017

E3 Ligase RNF126 Directly Ubiquitinates Frataxin, Promoting Its Degradation: Identification of a Potential Therapeutic Target for Friedreich Ataxia.

Cell reports
2017

Exosome-Based Delivery of miR-124 in a Huntington's Disease Model.

Journal of movement disorders
2016

Is There an Association of Physical Activity with Brain Volume, Behavior, and Day-to-day Functioning? A Cross Sectional Design in Prodromal and Early Huntington Disease.

PLoS currents
2015

Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.

Drug design, development and therapy
2015

Examining Huntington's disease patient and informant concordance on frontally mediated behaviors.

Journal of clinical and experimental neuropsychology
2015

The stability and activity of human neuroserpin are modulated by a salt bridge that stabilises the reactive centre loop.

Scientific reports

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença neurodegenerativa genética.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença neurodegenerativa genética

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Spatially resolved lipids in a mouse brain model of globoid cell leukodystrophy via IR-MALDESI MSI and parallel reaction monitoring MSI.
    Analytical and bioanalytical chemistry· 2026· PMID 41578040mais citado
  2. Short Review on Currently Used Sample Preparation and Determination Methods of Risdiplam.
    Journal of separation science· 2025· PMID 40355367mais citado
  3. Episodic headaches and cognitive decline: uncovering neuronal intranuclear inclusion disease in a young patient.
    BMJ case reports· 2025· PMID 39753283mais citado
  4. Assessment of Fine Motor Abilities Among Children with Spinal Muscular Atrophy Treated with Nusinersen Using a New Touchscreen Application: A Pilot Study.
    Children (Basel, Switzerland)· 2025· PMID 41153560mais citado
  5. Poly ADP-ribose signaling is dysregulated in Huntington disease.
    Proceedings of the National Academy of Sciences of the United States of America· 2024· PMID 39331414mais citado
  6. Wild-type huntingtin in neurodevelopment.
    J Huntingtons Dis· 2026· PMID 41955484recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:183500(Orphanet)
  2. MONDO:0024237(MONDO)
  3. GARD:20280(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q19001236(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Doença neurodegenerativa genética
Compêndio · Raras BR

Doença neurodegenerativa genética

ORPHA:183500 · MONDO:0024237
MedGen
UMLS
C0751870
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades